



LUND UNIVERSITY
Faculty of Medicine

LUP

Lund University Publications

Institutional Repository of Lund University

This is an author produced version of a paper published in *Placenta*. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:
K May, L Wester Rosenlöf, M G Olsson, M Centlow, M Mörgelin, I Larsson, M Cederlund, S Rutardottir, W Siegmund, H Schneider, B Åkerström, S Hansson

"Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by alpha(1)-microglobulin."

Placenta 2011 32, 323 - 332

<http://dx.doi.org/10.1016/j.placenta.2011.01.017>

Access to the published version may require journal subscription.

Published with permission from: Elsevier

Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by α_1 -microglobulin

Karen May^{1,2#}, Lena Rosenlöf^{3#}, Magnus G. Olsson³, Magnus Centlow¹, Matthias Mörgelin³, Irene Larsson¹, Martin Cederlund³, Sigurbjörg Rutardottir³, Werner Siegmund², Henning Schneider⁴, Bo Åkerström^{3§}, and Stefan R. Hansson^{1§}

¹Division of Obstetrics and Gynecology, Department of Clinical Sciences, Lund University Hospital, Lund University, Lund, Sweden

²Department of Clinical Pharmacology, Ernst Moritz Arndt University of Greifswald, Germany

³Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden

⁴Department of Obstetrics and Gynecology, Insel Spital, University of Bern, Switzerland

#) Both authors contributed equally to the work.

§) To whom correspondence should be addressed:

Stefan Hansson, BMC C1416b, University of Lund, Box 117, SE-22100 Lund, e-mail:

stefan.hansson@med.lu.se

Bo Åkerström, BMC B14, University of Lund, Box 117, SE-22100 Lund, e-mail:

bo.akerstrom@med.lu.se

The paper was presented at IFPA, Santiago 2010.

Short Title: **"Free hemoglobin causes preeclampsia-like injuries *ex vivo*"**

Key words: hemoglobin, oxidative stress, dual placental perfusion, microarray, electron microscopy, α_1 -microglobulin

Abbreviations

| | |
|-------|--|
| A1M | α_1 -microglobulin |
| ECM | extra-cellular matrix |
| GAPDH | glyceraldehyde-3-phosphate dehydrogenase |
| PE | preeclampsia |
| Hb | hemoglobin |
| HbA | adult hemoglobin |
| OxyHb | oxygenated hemoglobin |
| HbF | fetal hemoglobin |
| ROS | reactive oxygen species |
| EM | electron microscopy |
| BASE | BioArray Software Environment |
| RIA | radioimmunoassay |

Abstract

Background: Preeclamptic women have increased plasma levels of free fetal hemoglobin (HbF), increased gene expression of placental HbF and accumulation of free HbF in the placental vascular lumen. Free hemoglobin (Hb) is pro-inflammatory, and causes oxidative stress and tissue damage.

Methodology: To show the impact of free Hb in PE, we used the dual *ex vivo* placental perfusion model. Placentas were perfused with Hb and investigated for physical parameters, Hb leakage, gene expression and morphology. The protective effects of α_1 -microglobulin (A1M), a heme- and radical-scavenger and antioxidant, was investigated.

Results: Hb-addition into the fetal circulation led to a significant increase of the perfusion pressure and the feto-maternal leakage of free Hb. Morphological damages similar to the PE placentas were observed. Gene array showed up-regulation of genes related to immune response, apoptosis, and oxidative stress. Simultaneous addition of A1M to the maternal circulation inhibited the Hb leakage, morphological damage and gene up-regulation. Furthermore, perfusion with Hb and A1M induced a significant up-regulation of extracellular matrix genes.

Significance: The *ex vivo* Hb-perfusion of human placenta resulted in physiological and morphological changes and a gene expression profile similar to what is observed in PE placentas. These results underline the potentially important role of free Hb in PE etiology. The damaging effects were counteracted by A1M, suggesting a role of this protein as a new potential PE therapeutic agent.

Introduction

Preeclampsia (PE) is a leading cause of maternal and fetal morbidity and mortality. Despite extensive research, PE still remains enigmatic and is called the disease of theories by many obstetricians [1]. Clinical manifestations, i.e. hypertension and proteinuria, appear from 20 weeks of gestation and onwards, but the underlying mechanisms may begin already at the time of implantation [2]. Up to date, there are no established prognostic and/or diagnostic markers for the disease. The only cure still is termination of pregnancy with delivery of the fetus and removal of the placenta.

PE evolves in two stages where the first stage is initiated by a defective placentation. A growing body of studies shows that uneven blood perfusion, hypoxia and oxidative stress follow as a consequence of the defect in placentation, further aggravating the impairment of placental functions [3, 4]. Stage two is characterized by the appearance of clinical symptoms such as hypertension, proteinuria and edema, which are caused by a general vascular endothelial dysfunction leading to a general organ failure and damage. The link between stage one and two is still unclear but several different factors and explanations have been suggested [5].

By using gene and protein profiling techniques, we have previously been able to show increased mRNA levels of fetal hemoglobin (HbF) in the placental tissue and evidence of free HbF in the placental vascular lumen in PE [6]. Furthermore, we have shown increased plasma and serum concentrations of HbF in the mother, suggesting that free HbF leaks over the blood-placenta barrier, into the maternal circulation where the plasma concentration is increasing from early pregnancy and later correlates to the severity of the the disease [7, 8].

Free Hb is a highly reactive molecule that is capable of damaging and disrupting cell membranes [9]. Also, it binds and inactivates nitric oxide (NO)[10], with vasoconstriction as a consequence. The metabolites of Hb, free heme and iron, damage lipids, protein and DNA through direct oxidation and/or generation of reactive oxygen species (ROS) [11]. In fact, free heme, bilirubin, and biliverdin have been identified among 14 metabolites in a metabolomic signature of preeclampsia using first trimester plasma [12]. Due to the lipophilic nature of the heme-group, it intercalates membranes and has destabilizing effects on the cytoskeleton [13]. Heme is also a pro-inflammatory molecule that activates neutrophils [11]. Several important Hb-detoxification systems work in parallel to prevent Hb-induced oxidative stress and tissue damage. Haptoglobin is a glycoprotein that forms a complex with free Hb, and is one of the primary Hb scavengers in plasma. In fact, a haptoglobin polymorphism has been associated with essential hypertension, which is predisposing for developing PE [14]. Free heme is primarily scavenged by hemopexin, but this activity is reduced in PE [15]. The haptoglobin-Hb and hemopexin-heme complexes are cleared from the circulation by the two receptor-mediated pathways CD163 and CD91, and subsequently degraded in lysosomes [16].

α_1 -microglobulin (A1M), a 26kDa plasma and tissue protein, has recently been described as a heme- and radical scavenger with antioxidative, cell-protective and repair properties [17-20]. A1M is mainly synthesized in the liver and distributed via the blood-stream to the extra-vascular compartment in all tissues [21]. Due to its small size, A1M is filtered in the renal glomeruli and partially re-absorbed in the tubuli [21, 22]. Recent reports have shown that A1M is a heme- and radical-scavenger, involved in the defense against

oxidative stress induced by free Hb and participating in the degradation of heme [18, 19, 23]. Its synthesis is up-regulated, both in liver and peripheral cells, as a consequence of elevated concentrations of free Hb, heme and ROS [24].

We have hypothesized, that early events, including hypoxia, during development of PE cause over-production and release of free HbF, which induces oxidative stress with damage to the blood-placenta barrier and leakage of free HbF into the maternal circulation. Thus, circulating free HbF may be one of the important factors, linking stage 1 to stage 2, leading to endothelial dysfunction and subsequently the clinical manifestations characterizing PE. The levels of A1M are elevated in maternal plasma, serum, urine and placental tissue from women with PE suggesting that the protein is involved in a defence reaction against the Hb-insult [8]. Hypothesizing that A1M, and other defence systems, are overwhelmed in PE, we propose that the disease may be treated by addition of exogenous A1M.

In this study we used the dual placental perfusion system, which is a well-established model to study the placental function *ex vivo* [25], in order to systematically decipher the effects of free Hb in an isolated healthy placenta. We have previously shown that *ex vivo* perfusion of human placenta under control conditions leads to mild oxidative stress with changes resembling those described *in vivo* in PE, such as increased secretion of pro-inflammatory cytokines and release of syncytiotrophoblast membranes [26-28]. Physical and morphological parameters were recorded and related to the global gene expression and electron microscopy (EM) data. Furthermore, the protective and potentially therapeutic effects of A1M were evaluated.

Material and Methods

Sample Collection

Fifteen human term placentas (gestational age 38-42 weeks, placenta weight 438-1102 g) obtained from uncomplicated singleton pregnancies delivered by Caesarean section (n=3) or vaginal delivery (n=12) were used for the perfusion experiments. All mothers gave their written informed consent for the experimental use of their placentas prior to delivery. The ethical review committee of Lund University approved the study.

Tissue samples from the placenta were taken from an adjacent cotyledon before the perfusions were initiated and from the perfused cotyledon after the completion of the perfusion. Furthermore, placental tissue samples were also collected from three patients with severe PE (diastolic pressure >110mmHg and proteinuria >3g/L). Small pieces, 3x3mm, were obtained from a central, non-necrotic, part of the placenta and immersed in fixative as described below. The tissue samples were immediately cryopreserved for gene expression and protein analysis.

The Placental Perfusion Model and Experimental Design

The perfusions of a placental cotyledon using the dual perfusion model were performed as previously described [25](Supplementary figure 1). When the volumes and pressures of both the maternal and fetal circuits were stable the circuits were closed and perfusion continued with mean flow rates of 12 and 4 ml/min on the maternal and fetal side respectively and 140 ml perfusion medium were recycled in each circulation. The perfusion medium consisted of NTCT 153 (Sigma-Aldrich, Steinheim, Germany) in

Earl's buffer (1:3, v/v), 4% albumin (PAA, Laboratories, Linz, Austria), 0.2% glucose (Merck, Darmstadt, Germany), 1% dextrane 40 (Carl Roth, Karlsruhe, Germany), 2500 units/l heparin (Leo Pharma, Malmö, Sweden), and 250 mg/l clamoxyl (AstraZeneca, Lund, Sweden). To mimic intrauterine conditions, two gas exchange devices were connected (Mera Silox-S 0.3, Senko Medial Instruments, Tokyo, Japan). The fetal circulation was equilibrated with 95% nitrogen and 5% carbon dioxide and an atmospheric gas mixture was used for the maternal side.

The experiments were terminated if any of the following criteria was observed: fetal perfusion pressure above 50 mmHg, loss of perfusate > 4 ml/h, and in case of mismatch of materno-fetal circulation as measured by inadequate oxygen transfer (pO_2 maternal side < 100 mmHg, pO_2 fetal side < 20 mmHg). After 60 minutes of the initial equilibration of the placental preparation, the medium was exchanged in both circuits and the actual experiment consisted of three phases lasting 120 min each with medium exchange between the phases. Experiments were performed using medium only in phase I and III. In phase II the medium was supplemented with one of the following substances: 3 mg/ml free human adult Hb (HbA; corresponding to 55 μ M Hb or 220 μ M heme) in the fetal circulation (n=6, Hb), 0.5 mg/ml A1M (22 μ M) in the maternal circulation (n=2, A1M) or 3 mg/ml free HbA in the fetal + 0.5 mg/ml A1M in the maternal circulations respectively (n=4, Hb+A1M). Control experiments were performed using medium only in all three phases (n=3).

HbA was purified from whole blood, freshly drawn from healthy subjects as described [29]. Recombinant human A1M was expressed in *E.coli*, purified and re-folded as described by Kwasek et al [30], but with an additional ion-exchange chromatography

step. This was performed by applying A1M to a column of DEAE-Sephadex A-50 (GE Healthcare, Uppsala, Sweden) equilibrated with 20 mM Tris-HCl, pH8.0. A1M was eluted with a linear salt gradient (from 20 mM Tris-HCl, pH8.0 to 20mM Tris-HCl+0.2 M NaCl) at a flow rate of 1 ml/min. A1M-containing fractions, according to absorbance at 280 nm, were pooled, concentrated and dialyzed against perfusion medium.

Medium samples were taken at regular intervals from the maternal and fetal circulation and stored at -20°C for further analysis. Glucose consumption and lactate production were used as parameters reflecting the placental energy metabolism. Antipyrine (0.4 mM) and creatinine (1.3 mM) permeability were measured in phase I, as reference parameters for trans-placental transfer of flow- respectively diffusion limited molecules to ensure a match of the materno-fetal circulation. Glucose, lactate and creatinine concentration as well as oxygen and carbon dioxide pressure were measured using a blood-gas-analyzer (Radiometer, Copenhagen, Denmark); antipyrine concentration was measured using an HPLC method [31]. The arterial fetal perfusion pressure and the feto-maternal leakage were recorded as viability characteristics.

Transmission Electron Microscopy

The ultra-morphology of the placental samples were analyzed by ultra-thin sectioning and transmission EM. The placenta specimens were immersed in 1.5% paraformaldehyde, 1.5% glutaraldehyde in 0.1M sodium-phosphate buffer pH 7.2 for 1h at room temperature, and then overnight at 4 °C. Samples were washed in the fixation buffer and then postfixed for 1h at room temperature in 1% osmium tetroxide in 0.1M sodium-phosphate buffer, dehydrated in a graded series of ethanol, and then embedded in Epon

812 using acetone as an intermediate solvent. Specimens were cut into 50-70 nm-thick ultrathin sections with a diamond knife on an LKB ultramicrotome. The sections were stained with uranyl acetate and lead citrate. Specimens were observed in a JEOL JEM 1230 electron microscope operated at 80 kV accelerating voltage, and images were recorded with a Gatan Multiscan 791 CCD camera. The analysis was carried out in a blinded fashion by an independent investigator. For quantitative evaluation of tissue damage by oxidative stress, the surface areas of mitochondria and extracellular matrix space as well as the ratio of damaged and intact plasma and nuclear membrane stretches were determined for 30 cell profiles (Table 1). The values for the surface area for these structures were determined using Adobe Photoshop CS5.

Gene Expression

RNA Extractions and Integrity

Total RNA was extracted using TRIZOL[®] (Invitrogen, Carlsbad, USA) and E.Z.N.A[™] total RNA Kit (Omega Bio-tek, Doraville, USA) according to manufacturer's instructions. RNA concentration was spectrophotometrically determined using a Nanodrop (NanoDrop technologies, Wilmington, USA). RNA integrity was assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA). Only samples with a RNA integrity number over 6 were used for expression profiling.

cDNA Synthesis

RNA was transcribed using either the Taqman Reverse Transcription Reagents from Applied Biosystems (Applied Biosystems Inc., Foster City, CA, USA) or Fermentas RevertAid H Minus first strand cDNA synthesis kit (Fermentas AB, Helsingborg,

Sweden) according to the manufactures instructions. The cDNA samples were stored at -20°C until further use.

Arrays

Human whole genome bead microarrays, HumanHT-12 v3 Expression BeadChip (Illumina Inc., San Diego, CA, USA) were ordered from SCIBLU Genomics at the Lund University, Sweden and used according to the manufacturer's instructions. Following hybridization and scan, the arrays were imaged on an Illumina BeadArray™ Reader (Illumina Inc.).

Array Analysis

Expression data was exported into BioArray Software Environment (BASE) for statistical analysis [32]. Data was normalized using average normalization and non-specific hybridizations were removed by filtering with a p-value < 0.01 using the Illumina p-value detection analysis. Arrays were then background corrected and exported into TM4 MeV for further analysis [33].

Firstly, all genes not present in 95% of the arrays were filtered out. Then, data were log₂ transformed and the differential gene expression was calculated with a false discovery rate modified t-test. P-values were set to be based on the maximum number of permutations for the analysis, and the cut-off was set to $q < 0.05$ and $p < 0.05$. Fold change was calculated by dividing the mean intensity for each gene between the groups.

Real-time PCR

Gene transcripts for verification of microarray results were quantified in the StepOnePlus™ Realtime PCR System (Applied Biosystems) using commercially available TaqMan® Gene Expression Assays (Applied Biosystems) (Supplementary table 1). The PCR reactions were carried out in duplicates including negative controls (without template) in each run as previously described [6]. Gene transcript of the A1M gene was quantified using SYBR green in an iCycler Thermal Cycler (Bio-Rad Laboratories, Hercules, CA, USA) as previously described [20].

Protein Measurements

Measurement of Hb in medium

Hb was measured in the perfusion medium using HemoCue Plasma/Low Hb according to the manufacturer (Hemocue, Ängelholm, Sweden).

Protein extraction

Total protein from the placental tissues was isolated using TRIZOL® (Invitrogen) according to the manufacturer's instructions. The total protein concentration was determined by BCA™ protein assay kit (Pierce, Thermo scientific Rockford IL USA). The protein solutions were corrected to the same concentrations before analysis.

Radioimmunoassay (RIA) of A1M

Radiolabelling of A1M with ¹²⁵I was done using the chloramine T method [34]. Labeled A1M was separated from free iodide by gel-chromatography on Sephadex G-25 columns (PD10, GE Healthcare, Uppsala, Sweden). A specific activity of 0.1-0.2 MBq/μg protein was obtained. RIA was performed as previously described [35].

SDS-PAGE and Western blotting

SDS-PAGE (T=12%, C=3.3%) was performed as described by Laemmli [36]. The gels were run under non-reducing conditions. The separated proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon-P, Millipore, Bedford, MA, USA). The PVDF membranes were then incubated over-night as described [37] with mouse monoclonal anti-A1M antibodies (BN11.10, 10 µg/ml) [38], followed by incubation with ¹²⁵I-labelled rabbit anti-mouse IgG (10 ng/ml; Dako, Denmark). The membranes were developed in a Fuji FLA3000 phosphoimaging system (Fujifilm Sweden AB, Stockholm, Sweden). Human free, monomeric plasma A1M, used as control, was purified by affinity chromatography and gel chromatography as described [39].

Statistical Analysis

All statistical analysis was performed using Origin 8 software (Microcal, Northampton, MA, USA). The significance of differences between groups was evaluated using both Student's t-test and Mann-Whitney U-test. Values of $p < 0.05$ were considered statistically significant.

Results

Validation Parameters and Characteristics of the Placental Perfusions

Initially, in phase I, antipyrine and creatinine permeability were monitored in all four perfusion groups (control, Hb, Hb+A1M and A1M) to ensure that there was no mismatch of the maternal and fetal circulation before the supplements were added in phase II. No difference between the perfusions was detected (Supplementary table 2). The validation parameters for placental carbohydrate metabolism, glucose consumption and lactate production, were investigated for all perfusion groups in phase I-III (Supplementary table 2). None of the supplements influenced any of these parameters and no difference between the individual phases of the perfusion experiments was detected. Antipyrine and creatinine permeability and glucose consumption and lactate production were all found to be consistent with previous studies [31].

Hemoglobin Increases Perfusion Pressure and Feto-Maternal Hemoglobin Leakage.

Addition of Hb into the fetal circulation led to significant increase of the mean arterial fetal perfusion pressure compared to control perfusions (14.3 ± 2.9 mmHg vs. 3.7 ± 2.0 mmHg, $p=0.019$, Fig. 1A). The elevated perfusion pressure in the fetal circulation caused a tendency to higher feto-maternal leakage, measured as a volume increase in the maternal circulation, although this change was not statistically significant (Fig 1B). The specific leakage of free Hb from the fetal into the maternal circulation increased with time (Fig 1C).

Free Hemoglobin Damages Placental Ultra Morphology

The morphology of cytotrophoblasts and syncytiotrophoblasts in placental villi of Hb-perfused and control placentas was analyzed by EM (overview Figure 2, quantification Table 1). Exposure to free Hb resulted in severe cell-damage revealed by alterations of the extracellular matrix (ECM) architecture (Fig. 3B), signs of apoptosis manifested by the presence of vast amounts of apoptotic vesicles (Fig. 3D) and enlarged mitochondria (Fig. 3F). In the pericellular environment the Hb-perfusion caused impaired cellular barrier functions including plasma membrane rupture (Fig. 3D). Intracellularly, the Hb-perfusion caused enlarged mitochondria, altered endoplasmatic reticulum structure and a fuzzy morphology of nuclear membranes (Fig. 3F, H). For further details see legend of figures.

The damages observed in the Hb-perfused placentas were compared to non-perfused placenta samples taken at delivery from patients with severe PE. The morphology seen in PE-placentas (Fig. 4C) was similar to the morphology of placentas perfused with Hb (Fig. 4B). The controls and the non-perfused placentas from healthy subjects showed no signs of damage and no difference in morphology (Fig. 4A).

Microarray Analysis

The gene expression was analyzed by microarray before and after perfusions. The differential gene expression between Hb vs. controls, Hb+A1M vs. Hb, Hb+A1M vs. A1M and A1M vs. control, respectively, showed a significantly differential gene

expression of in total 818 genes when a cut-off was set to $p < 0.05$ and $q < 0.05$ (supplementary table 3). For the complete list of genes with significantly changed expression see supplementary table 4.

Free Hemoglobin Up-regulates Placental Gene Expression.

Simply by looking at the numbers of the microarray Hb vs. control comparison, it can be concluded that Hb perfusion resulted in a general up-regulation of genes (184 up and 5 down). The major gene categories affected were genes related to immune response, apoptosis, oxidative stress, structure and cytoskeleton (Table 2). This suggests that Hb perfusion results in oxidative stress, apoptosis and tissue damage, supporting the morphological changes observed by EM. Among the down-regulated genes, the pregnancy specific beta-1-glycoproteins 3 and 7 are of particular interest because down-regulation of these has previously been correlated to PE and poor pregnancy outcome [40].

To confirm the microarray data we quantified the expression of genes of particular interest (i.e. greatest and/or most statistically significant differentially expression, gene ontology and expression pattern) using quantitative real-time PCR. The addition of Hb led to a significant up-regulation of DNA repair/apoptosis pathways (represented by poly-(ADP-ribose)-polymerase family, member 3; PARP3 and immune response pathways (represented by Fc-fragment of IgG, high affinity IA, receptor (CD64); FCGR1A. We also found a strong tendency to down-regulation of pregnancy specific beta-1-glycoprotein 3 and 7 genes (PSG3 and 7).

AIM-Addition Protects the Placenta from the Hemoglobin insult

Addition of A1M into the maternal circulation simultaneous to addition of free Hb to the fetal circulation did not reverse the increased perfusion pressure caused by Hb. A slight increase, but not statistically significant, was seen by addition of A1M alone (Fig 1A). No significant change in leakage of fluid was seen by addition of A1M (Fig 1B). However, A1M significantly prevented the specific leakage of free Hb from the fetal into the maternal circulation (Fig 1C).

A protective effect by A1M-addition was also supported by the EM observations. The ECM architecture in the placentas perfused with Hb+A1M was indistinguishable from the controls (Fig. 5D, B, Table 1). Likewise, the cell organelle structures were intact in the groups, i.e. no swelling of mitochondria, no disruption of the membranes, and absence of apoptotic vesicles could be seen (data not shown). Placentas perfused with A1M alone could not be distinguished from the control placentas (data not shown).

A1M Influence on Hemoglobin-Induced Gene Expression in Placenta

In an attempt to explore the mechanisms behind the protective effects of A1M, the microarray data from perfusions with Hb+A1M, Hb (alone) and Hb+A1M vs. Hb were compared. The analysis shows a general down-regulation of genes (236 down and 42 up) (supplementary table 3). This suggests that the simultaneous addition of A1M to the maternal circulation counteracted the general gene up-regulation caused by Hb perfusion. In order to confirm this finding we compared the list of genes up-regulated in Hb vs. control to the list of genes down-regulated in Hb+A1M vs. Hb. In total, twelve genes that were up-regulated in Hb vs. control, were down-regulated in Hb+A1M vs. Hb (see supplementary table 4). Among these were genes related to oxidative stress-response and

apoptosis e.g. arginine-rich, mutated in early stage tumors, (ARMET) and immune response e.g. RAS-like, family 11, member B (RASL11B) (Table 3). The expression of these genes was not affected by the addition of A1M alone. Interestingly, several genes coding for ECM components e.g. collagen, type VIII, alpha 2, (COL8A2), were up-regulated in placentas perfused with Hb+A1M. These genes were not up-regulated when Hb or A1M were added separately to the circulations.

To confirm the microarray data, we quantified a selection of genes by real-time PCR. The results confirmed that A1M-addition counteracted the up-regulation of oxidative genes (represented by ARMET) and immune response genes (represented by RASL11B). Also, the up-regulation of ECM genes (represented by COL8A2) by Hb+A1M, but not by either protein separately, was confirmed.

All together, the gene expression data suggest that A1M acts protectively by counteracting harmful oxidative consequences of the Hb-perfusion by down-regulating oxidative, apoptotic and immune related genes and up-regulation of ECM protective/repair genes.

Expression of A1M mRNA and A1M Protein Variants in Placenta

To further explore the mechanism of A1M-protection in the Hb-perfusion insult, we investigated A1M mRNA and protein content and the qualitative presence of various A1M variants in the placental tissue from the study groups.

Real-time PCR revealed an up-regulation of A1M mRNA expression in the Hb perfused placentas (Fig. 6A). Furthermore, addition of exogenous A1M resulted in decreased A1M mRNA expression, almost to the same level as the control placentas. Perfusion with A1M

alone did not yield a significant change in A1M mRNA expression compared to control perfusions.

The A1M-protein concentration in the placental tissue was also increased by Hb-perfusion as compared to controls (Fig. 6B). The addition of A1M to the maternal circulation resulted in a dramatic increase of the A1M-concentration in the placental tissue. This was observed both with and without the addition of free Hb to the fetal circulation and could reflect A1M-protein in the medium from the intervillous space and/or in the tissue.

Variants of the A1M-protein in (Hb+A1M)-perfused placental tissues were also qualitatively analyzed by Western blotting (Fig. 6C). Monomeric plasma A1M (lane 2) migrates as a 31 kDa-band and is found in whole plasma (lane 1) and placental tissue (lane 3). Also, high molecular weight A1M-complexes with IgA, albumin and prothrombin {Berggård, 1997 #2368}, migrating between 100-400 kDa, were found in plasma and placenta tissue. Non-glycosylated recombinant *E.coli*-A1M, migrating as a 24 kDa band, was found in large amounts in the placental tissue (lane 3), suggesting an uptake of A1M from the maternal circulation, or the presence of A1M-containing medium. In addition to these previously described forms, several novel variants were seen in the placental tissue (lane 3). The most prominent of these forms migrated at 33, 35, 45 and 100 kDa. The former three bands were seen in all perfusions, whereas the latter was seen only in some, but not all, Hb+A1M-perfusions.

Discussion

Placental tissue may be subjected to different degrees of oxidative stress. Recently, it was shown that labor initiates oxidative stress which, depending on length and intensity, varies with the lowest degree of stress found in placental tissue from elective cesarean section [41]. As far as the gene profile is concerned, there apparently is no unanimous opinion [42]. Oxidative stress related changes in placental tissue is a typical hallmark of PE [3]. *Ex vivo* dual perfusion of placental tissue, even under control conditions, induces mild oxidative stress, which may be explained by reperfusion following the postpartum ischaemia [27]. We have also shown that addition of xanthine + xanthine oxidase to the medium only resulted in a minor increase of oxidative stress indicating a considerable antioxidant capacity of the tissue [43]. The gene expression profile in *ex vivo* perfused placental tissue shows similarities with tissue from PE placenta [28].

In this paper we have obtained results supporting our hypothesis that free Hb may have a central role in the etiology of PE. Perfusion with free Hb led to increased perfusion pressure, feto-maternal Hb leakage, ultra-structural changes of the ECM and general cell damage. Gene array analysis showed an up-regulation of genes related to apoptosis and oxidative stress-response. The morphological alterations showed a high similarity to those observed in PE placentas [44]. Furthermore, the results also suggest that the heme- and radical scavenger AIM can prevent several of the harmful effects of the Hb-insult.

The similarity between the ultra-structural alterations in our *ex vivo* Hb-perfused placental tissue and unperfused placental tissue from PE patients suggests that our model

is relevant and underline the impact of Hb in the PE etiology. In addition, the observed ultra-structural alterations are, to some extent, in agreement with a previously published study on endothelial cell damage in PE [44]. In our EM analysis we have mainly focused on the plasma membrane structure, ECM architecture and organelle morphology of syncytio-/cyto-trophoblasts. However, several additional ultra-structural observations were seen in the syncytiotrophoblast layer in the Hb-perfused placentas. Signs of cell death, dilated endoplasmatic reticulum and swollen cells with damaged plasma membranes are some of the changes that are agreement with findings from villous explants subjected to oxidative stress [45].

Our observations of the effects of Hb-perfusion in placental tissue may be explained in terms of known toxic effects of free Hb and its metabolites. As described above, cell-free Hb and its metabolites are known to be harmful because of their oxidative properties. OxyHb, i.e. ferrous Hb (Fe^{2+}) binding oxygen (O_2), is known to undergo spontaneous intramolecular oxidation–reduction reactions which generate superoxide radicals. Further reactions lead to formation of ferryl Hb (Fe^{4+}), free heme, and various ROS. All these compounds are toxic because they can cause oxidative damage on DNA, matrix molecules, cell membranes, and other tissue components [46]. Thus, it is reasonable to assume that Hb-induced oxidations are explanatory mechanisms of the disruption of the placental ultrastructure as well as the increased feto-maternal leakage.

The results of the genome wide array analysis support the idea that free Hb mediates the placental damage via oxidation. Hb-perfusion, in general, led to a massive up-regulation

of genes. The gene ontology-analyses showed that apoptosis-, oxidative stress-, and immune-related genes were frequently represented, confirming data from previously reported findings based on gene array studies on PE placentas [6, 47-49].

Assuming that Hb mediates the placental damage via heme and oxidative stress, the heme- and radical scavenging and cyto-protective properties of A1M could explain the inhibition of Hb-induced damage [18, 19, 21, 50]. For example, when cell cultures were exposed to free Hb, heme, Fenton reaction-generated ROS and irradiation, addition of A1M led to heme-binding, decreased ROS-levels and inhibition of cell death and oxidative stress markers in the cells [8, 20]. The exact mechanism behind the scavenging effects by A1M still remains to be explored. Besides radical scavenging, our results suggest that A1M exerts protective effects by up-regulation of genes related to ECM components, (e.g. collagen, type VIII, alpha 2, COL8A2) in the presence of Hb. It may be speculated that A1M in this way also activates systems that repair tissue damages caused by oxidation.

The increase in arterial pressure by the Hb-perfusion may be a result of oxidative endothelial damage but it is also likely to be an effect of the NO-scavenging properties of free Hb. It has previously been shown that hemolysis and increased levels of cell-free Hb in sickle-cell anemia results in binding of NO by oxy-Hb, thus inhibiting the vasodilatory function of NO [51]. The addition of A1M did not prevent the rise in perfusion pressure induced by Hb. A possible explanation for this may be that the protective effects of A1M does not include inhibition of the NO-scavenging properties of

Hb. This speculation seems reasonable, since A1M has not been reported to bind directly to the Hb molecule itself.

The concentration of Hb in the perfusion media was 3 mg/ml, which is equivalent to 220 μ M heme-groups. This is much higher than the Hb-concentrations, 3-10 μ g/ml, measured in PE-patients at 20 weeks of gestation or at term [7, 8]. A higher concentration was chosen for several reasons. First, the local concentration of free Hb in the placental villi can be expected to be much higher than in the maternal blood and secondly, the exposure time of the perfused placental tissue to free Hb is only a few hours compared to several weeks in the clinical situation. An A1M concentration of 22 μ M, corresponding to a tenfold excess of Hb, *visavi* A1M, was chosen because, as mentioned above, A1M does not interact with Hb itself but rather with free heme and radicals expected to be generated at a much lower steady-state concentration. In addition, the radical-scavenging capacity of A1M was shown to be approximately 8-9 radicals / A1M-molecule [24]. It has also been shown previously that a molar deficit of A1M is sufficient to protect cultured cells against oxidation by an excess of Hb or free heme [20].

Interestingly, several unique forms of A1M were identified in the placenta tissue extracts (33, 35, 45 and 100 kDa bands in Western blotting). The former three variants were seen in all samples, suggesting that they are constitutively present in placenta, and not derived from exogenously added recombinant A1M. The 45 and 100 kDa bands have been described previously and were suggested to be complexes between A1M and other proteins [52]. The previously un-detected 33 and 35 kDa-bands are, due to their small

size, unlikely to be complexes with other proteins and they may represent A1M-forms with larger placenta-specific glycosylation modifications. Our results thus show the presence of unique placental variants of A1M suggesting a placenta-specific role of the protein.

A physiological role of A1M in the protection of human placenta is further supported in previous studies on the immunohistochemical distribution of A1M [20, 52]. The protein was found to be present throughout the villous stroma, with an accumulation on the apical surface of the syncytiotrophoblast layer and in the basal membrane around the fetal blood vessels. This distribution is consistent with the hypothesis that A1M plays a role in local protection against oxidative stress at the maternal/placental and fetal/placental interfaces. Interestingly, high concentrations of A1M were found at sites of "syncytial injury", i.e. where the syncytiotrophoblast layer was ruptured, and at fibrin deposits around intravillous blood vessels [52]. This suggests an accumulation/up-regulation of A1M where the integrity of the placental barrier is breached and the placental tissue is exposed to oxidants from fetal or maternal blood. This is supported by this study where Hb-perfusion led to up-regulation of placental A1M-mRNA expression and accumulation of A1M protein in the placental tissue. Accordingly, increased production of (unique placental variants) of A1M may be a normal response to Hb-induced oxidative stress in placental cells, which is in line with a previous report of an up-regulated A1M-expression in blood cells exposed to Hb and ROS [24].

The up-regulation of A1M previously reported in PE suggests a natural antioxidative response that fails to neutralize the oxidative stress in PE. By supplementing the body with a bolus dose of A1M, a therapeutic level might be reached. The idea of preventing PE development by anti-oxidative treatment is not new. Several studies have evaluated the use of vitamin C and E in high-risk pregnancies in order to prevent the oxidative stress seen in PE. The results have failed to show a reduction in the rate of adverse maternal or perinatal outcomes related to pregnancy-associated hypertension [53, 54]. This does not disprove the oxidative nature of the disease, however, since the scavenging capacity of vitamin C is limited and the oxidized form, dihydroascorbate, which is formed by its oxidation, may also present an oxidative challenge in the tissues during the disease.

In summary, PE is a pathologic condition that is in need of improved, early diagnosis and therapeutic treatment. Recently, we have shown that elevated levels of free HbF and A1M in maternal plasma are indicators for PE, and a prognostic/diagnostic test based on these two parameters is under development [7, 8]. The results presented in this paper further underlines that Hb is a potential important etiological factor in the onset and progression of PE. We also show that a heme- and radical scavenger protein may protect the placenta from cell-damage. Therefore, we suggest heme- and radical-scavenging as a possible treatment of PE. The inhibition of Hb damage by A1M in our *ex vivo* model suggests A1M as a promising candidate for future PE therapy.

Acknowledgements

This work was funded by grants from the Swedish Research Council (5775, 7144), governmental ALF research grants to Lund University and Lund University Hospital, Marianne and Marcus Wallenberg foundation, Anna Lisa & Sven Erik Lundgrens foundation for Medical Research, the Royal Physiographic Society in Lund, the Foundations of Greta and Johan Kock and Alfred Österlund, the Swedish Foundation for International Cooperation in Research and Higher Education (STINT), the Blood and Defence Network, Lund University, Crafoord foundation, Magnus Bergvalls foundation, Maggie Stephens foundation, the Swedish Society for Medical Research and Preelumina AB.

Microarrays and protocols were obtained from the Swegene DNA Microarray Resource Center in Lund, supported by the Knut and Alice Wallenberg foundation through the Swegene consortium.

We particular like to express our gratitude to the staff at the delivery unit at Lund University Hospital for grateful help and assistance in tissue collection.

Tables

Table 1: Quantification of values for surface areas obtained by EM.

| Structures | Control | Hemoglobin | Hemoglobin + A1M |
|--|---------|------------|------------------|
| ECM integrity | 93% | 16% | 78% |
| Plasma membrane integrity | 96% | 36% | 83% |
| Nuclear membrane integrity | 95% | 37% | 88% |
| Mitochondrial cross section area (square μm) | 0.4 | 1.3 | 0.6 |

Table 2: Selection of differentially expressed genes in Hb perfusion compared to control medium perfusions.

| Gene | Symbol | P-value | FC | Gene ontology |
|---|--------|---------|------|---|
| IMMUNE RESPONSE | | | | |
| FC fragment of IgG, high affinity IA, receptor (CD64) | FCGR1A | 0.006 | 2.8 | high-affinity Fc-gamma receptor, pivotal role in the immune response |
| intercellular adhesion molecule 3 | ICAM3 | 0.007 | 2.3 | regulates leukocyte adhesion to blood vessels at sites of inflammation/injury |
| APOPTOSIS, OXIDATIVE STRESS | | | | |
| BCL2-associated athanogene 4 | BAG4 | 0.008 | 2.3 | silencer of death domains |
| carbonyl reductase 1 | CBR1 | 0.005 | 1.6 | catalyzes reduction of carbonyl compounds |
| poly (ADP-ribose) polymerase family, member 3 | PARP3 | 0.008 | 2.4 | Activated as early response to DNA breaks, required for DNA repair & apoptosis regulation |
| CELL ADHESION/CELL-CELL CONTACT | | | | |
| nexilin | NEXN | 0.0080 | 3.8 | Actin filament binding, focal contact, cell adhesion, migration |
| PROTEIN/VESICLE TRANSPORT | | | | |
| synaptogamin-like 2 | SYTL2 | 0.008 | 1.9 | RAB27A-dependent vesicle transport, secretion in e.g.NK and CTL cells |
| HEME SYNTHESIS | | | | |
| uroporphyrinogen III synthase | UROS | 0.009 | 2.2 | Enzyme in heme synthesis pathway |
| PLACENTA FUNCTION | | | | |
| pregnancy specific beta-1-glycoprotein 3 | PSG3 | 0.0090 | -1.2 | female pregnancy, low expression indicates bad placental function |
| pregnancy specific beta-1-glycoprotein 2 | PSG7 | 0.010 | -1.3 | Female pregnancy, low expression indicates bad placental function |

FC= Fold change. A positive FC corresponds to an increased gene expression in the Hb

perfusion

Table 3: Selection of genes with altered expression after addition of A1M to the maternal side in the perfusion.

| Gene | Symbol | FC Hb vs. med. | FC Hb+A1M vs. Hb | Gene ontology |
|--|---------|----------------------|------------------------|---|
| IMMUNE RESPONSE | | | | |
| RAS-like, family 11, member B | RASL11B | 2.0 | 0.53 | intracellular signaling, GTP binding, cell communication |
| carboxypeptidase M | CPM | NC | 0.61 | proteolysis, catalytic activity |
| OXIDATIVE STRESS | | | | |
| connexin 40 | GJA5 | 2.0 | 0.52 | gap junction channel activity, blood vessel development |
| arginine-rich, mutated in early stage tumors | ARMET | 1.6 | 0.59 | receptor binding, growth factor activity |
| homocystein-/ER stress inducible, ubiquitin-like domain member 1 | HERPUD1 | 1.4 | 0.52 | biopolymer & protein metabolic process at ER membrane, stress inducible |
| CELL ADHESION/EXTRACELLULAR MATRIX | | | | |
| VAV 3 oncogene* | VAV3 | NC | 0.060 | integrin-mediated signaling pathway, cellular structure, morphogenesis, regulation of cell adhesion |
| collagen, type VI, alpha 2 | COL6A2 | NC | 1.7 | ECM structural constituent, cell adhesion, inorganic anion transport |
| collagen, type VIII, alpha 2 | COL8A2 | NC | 2.0 | ECM structural constituent, cell adhesion, collagen |

FC = Fold change. A positive fold change means the expression is increased in Hb (vs. medium) or Hb+A1M (vs. Hb only) respectively. NC=no statistically significant change in expression can be detected. *Also affected by A1M alone; A1M vs. medium FC 2.8.

Supplementary table 1: Data on primers used for real-time PCR amplification

| mRNA | Accession number | Size (NT) | TaqMan®Gene Expression Assay ID |
|---------|------------------|-----------|---------------------------------|
| GJA5 | NM_005266.5 | 89 | Hs00979198_m1 |
| ARMET | NM_006010.2 | 57 | Hs00180640_m1 |
| HERPUD1 | 3RefSeqs | 126 | Hs01124269_m1 |
| RASL11B | NM_023940.2 | 80 | Hs00225132_m1 |
| CPM | 3RefSeqs | 92 | Hs00266395_m1 |
| VAV3 | 2RefSeqs | 64 | Hs00196125_m1 |
| COL6A2 | NM_001849.3 | 89 | Hs00242484_m1 |
| COL8A2 | NM_005202.1 | 85 | Hs00697025_m1 |
| SYTL2 | 6RefSeqs | 107 | Hs00909223_m1 |
| UROS | NM_000375.2 | 124 | Hs00165992_m1 |
| NEXN | NM_144573.3 | 95 | Hs00332124_m1 |
| FCGR1A | NM_000566.3 | 105 | Hs00174081_m1 |
| ICAM3 | NM_002162.3 | 66 | Hs00233674_m1 |
| BAG4 | NM_004874.2 | 130 | Hs00362193_m1 |
| CBR1 | NM_001757.2 | 73 | HS00156323_m1 |
| PARP3 | 3RefSeqs | 88 | Hs00193946_m1 |
| PSG3 | NM_021016.3 | 96 | Hs00360732_m1 |
| PSG7 | NM-002783.2 | 101 | Hs00818333_m1 |
| GAPDH | NM_002046.3 | 122 | Hs99999905_m1 |
| ACTB | NM_001101.3 | 171 | Hs99999903_m1 |

Supplementary table 2: Viability characteristics during *ex vivo* perfusions of the human placenta. Means \pm S.D. are given.

| Protocol | Control | 3mg/ml Hb (fetal circulation) | 0.5mg/ml A1M (maternal circulation) | 3mg/ml Hb (fetal circulation)+ 0.5mg/ml A1M (maternal circulation) |
|---|-------------------|----------------------------------|--|---|
| | n=3 | n=6 | n=2 | n=4 |
| antipyrine permeability (ml \times min ⁻¹ \times g ⁻¹) ^A | 0.103 \pm 0.035 | 0.064 \pm 0.021 | 0.070 \pm 0.033 | 0.047 \pm 0.013 |
| creatinine permeability (ml \times min ⁻¹ \times g ⁻¹) ^A | 0.038 \pm 0.026 | 0.026 \pm 0.070 | 0.027 \pm 0.090 | 0.017 \pm 0.007 |
| glucose consumption (μ mol \times min ⁻¹ \times g ⁻¹) ^B | 0.392 \pm 0.343 | 0.333 \pm 0.106 | 0.422 \pm 0.140 | 0.196 \pm 0.063 |
| lactate production (μ mol \times min ⁻¹ \times g ⁻¹) ^B | 0.605 \pm 0.430 | 0.526 \pm 0.080 | 0.747 \pm 0.180 | 0.306 \pm 0.058 |

^A The materno-fetal permeability of antipyrine and creatinine were assessed in perfusion phase I, before addition of any of the supplements to ensure a match of the maternal and fetal circulation.

^B The overall (maternal and fetal) glucose consumption and lactate production are given as means of perfusion phase I-III, as there was no difference between the individual phases of the perfusion experiments.

Supplementary table 3: Overview of the differential gene expression between the various perfusion conditions detected by microarray.

| Perfusion condition | Number of up-regulated genes* | Number of down-regulated genes* |
|---------------------|-------------------------------|---------------------------------|
| Hb vs. medium | 184 | 5 |
| Hb+A1M vs. Hb | 42 | 236 |
| Hb+A1M vs. A1M | 67 | 106 |
| A1M vs. medium | 137 | 47 |

*The numbers of differential expressed genes when a cut off of $p < 0.05$ and $q < 0.05$ was used in the analysis.

Supplementary table 4: Genes with altered gene expression in the group comparisons. The p-value and fold change (within parenthesis) are presented. The fold change is always relative to the second group in the comparison, where a negative value represents decreased gene expression.

Figure Legends

Figure 1. Mean arterial fetal perfusion pressure, feto-maternal leakage of medium and Hb during *ex vivo* perfusions of the human placenta. The increase in fetal circulation pressure was detected at the end of phase II, and the feto-maternal leakage was detected at the end of phase III. The specific leakage of Hb in phase II is shown as concentration of Hb in the maternal circulation at various time-points. Means \pm S.E.M are given. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ in Hb vs. control. (*), (**), (***) represent the corresponding significance levels in Hb vs Hb+A1M perfusions.

Figure 2. Overview of ultrathin sectioning and transmission electron microscopy of human placenta. A and B shows an overview of a placental villus with the syncytiotrophoblast layer and the intervillous space seen at the top, from control medium (A) and Hb-perfused (B) placentas, respectively. The scale bar represents 5 μm . A higher magnification of A is shown in 2C and the frame in 2B is shown in 2D. The scale bars in Figure 2C and 2D represent 2 μm . The frames in Figure 2C (control medium perfused) and 2D (Hb-perfused) are shown as higher magnified areas in Figure 3A, C, E, G and 3B, D, F and H, respectively.

Figure 3. Ultrathin sectioning and transmission electron microscopy of human placenta perfused with control medium (A, C, E, G) or with Hb (B, D, F, H). The scale bar represents 0.2 μm . A, B: structural changes in the ECM upon Hb-perfusion with a dramatically reduced number of cross-striated collagen fibrils(c) in 3B. C, D: In control perfused placenta (3C) individual cells are surrounded by intact plasma membranes (PM) and adjacent, multi-layered electron dense structures (arrowheads). In contrast, Hb-

perfusion (3D) induces a massive presence of apoptotic vesicles (AV) and plasma membrane stretches of fuzzy electron density (arrow). E-F: after Hb-treatment (3F) mitochondria (M) increase considerably in volume and the morphology of the endoplasmatic reticulum (ER) with attached ribosomes changes from round, necklace-like structures (3E,3G) to an overall more extended shape (3F, 3H). In control specimens the nuclear membrane (NM) exhibits a typical double-layered structure with inner and outer membrane aspects (3G). After Hb-perfusion this is changed to a fuzzy and less defined appearance (3H).

Figure 4 Transmission electron microscopy of ultrathin sections of non-perfused healthy control placentas (A), as compared to placentas perfused *ex vivo* with Hb (B) or non-perfused PE placentas (C). The scale bar represents 0.5 μm . The ECM undergoes severe morphological changes upon Hb-perfusion, which resemble the morphology of non-perfused PE placentas, where for example an abundance of collagen fibrils in the healthy placenta (A) is altered to a relative thinness of matrix filaments and a massive presence of apoptotic membrane structures (B, C).




Figure 5. A1M prevents the damaging effects of Hb *ex vivo* on extracellular matrix as visualized by transmission electron microscopy of placenta specimens. The scale bar represents 0.2 μm . (A) non-perfused placenta, (B) perfusion with medium, (C) perfusion with Hb, (D) perfusion with Hb+A1M.





Figure 6. Expression of A1M as mRNA and protein and its variants in placental tissue. (A) A1M mRNA expression in placental tissue. The mRNA expression of A1M was analysed by real time PCR. The expression was related to the housekeeping gene









GAPDH. The data are presented as $\Delta\Delta Ct$ ($\Delta Ct_{A1M} - \Delta Ct_{GAPDH}$). Hb vs control: $p < 0.01$ and Hb+A1M vs Hb: $p < 0.07$. (B) A1M protein concentrations in placental tissue. The A1M protein concentration in total protein extracts of placental tissue was analysed by RIA. The data are presented as μg A1M/mg of total protein. Hb vs control: $p < 0.03$. (C) A1M variants in placental tissue. The A1M protein in placentas perfused with Hb+A1M was analyzed by Western blotting. 46 g total protein extracted from Hb+A1M perfused placenta were separated by SDS-PAGE (lane 3). As references 0.02 L human plasma (lane 1) and 10 g plasma free, monomeric A1M (lane 2) were co-analyzed. The A1M variants were detected with anti-A1M.



Suppl. Figure 1. Diagrammatic figure of the dual perfusion model





The maternal and fetal side respectively containing 140 ml perfusion medium that was recycled in each circulation.


















maternal circuit



fetal circuit

References

- [1] Roberts JM and Cooper DW. Pathogenesis and genetics of pre-eclampsia. *Lancet*. 2001;357(9249):53-6.
- [2] Lipstein H, Lee CC and Crupi RS. A current concept of eclampsia. *Am J Emerg Med*. 2003;21(3):223-6.
- [3] Roberts JM and Hubel CA. Is oxidative stress the link in the two-stage model of pre-eclampsia? *Lancet*. 1999;354:788-9.
- [4] Hung TH, Skepper JN, Charnock-Jones DS and Burton GJ. Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. *Circ Res*. 2002;90(12):1274-81.
- [5] Roberts JM and Hubel CA. The two stage model of preeclampsia: variations on the theme. *Placenta*. 2009;30 Suppl A:S32-7.
- [6] Centlow M, Carninci P, Nemeth K, Mezey E, Brownstein M and Hansson SR. Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes. *Fertil Steril*. 2008;90(5):1834-43.
- [7] Dolberg Anderson U, M.G. O, Rutadottir S, Centlow M, Heby Kristensen K, Isberg PE, Thilaganathan B, Åkerström B and Hansson SR. Fetal hemoglobin and alpha-1-microglobuline as first trimester markers for preeclampsia. *American J of Obstetrics and Gynecology*. 2011;in press.
- [8] Olsson MG, Centlow M, Rutardottir S, Stenfors I, Larsson J, Hosseini-Maaf B, Olsson ML, Hansson SR and Åkerström B. Increased levels of cell-free hemoglobin, oxidation markers, and the antioxidative heme scavenger α_1 -microglobulin in preeclampsia. *Free Radic Biol Med*. 2010;48(2):284-91.
- [9] Tsemakhovich VA, Bamm VV, Shaklai M and Shaklai N. Vascular damage by unstable hemoglobins: the role of heme-depleted globin. *Arch Biochem Biophys*. 2005;436(2):307-15.
- [10] Kim-Shapiro DB, Schechter AN and Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. *Arterioscler Thromb Vasc Biol*. 2006;26(4):697-705.
- [11] Kumar S and Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. *Toxicol Lett*. 2005;157(3):175-88.
- [12] Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, Roberts C, Cooper GJ, Kell DB and Baker PN. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. *Hypertension*. 2010;56(4):741-9.
- [13] Jarolim P, Lahav M, Liu SC and Palek J. Effect of hemoglobin oxidation products on the stability of red cell membrane skeletons and the associations of skeletal proteins: correlation with a release of hemin. *Blood*. 1990;76(10):2125-31.
- [14] Depypere HT, Langlois MR, Delanghe JR, Temmerman M and Dhont M. Haptoglobin polymorphism in patients with preeclampsia. *Clin Chem Lab Med*. 2006;44(8):924-8.
- [15] Bakker WW, Donker RB, Timmer A, van Pampus MG, van Son WJ, Aarnoudse JG, van Goor H, Niezen-Koning KE, Navis G, Borghuis T, Jongman RM and Faas MM.

Plasma hemopexin activity in pregnancy and preeclampsia. *Hypertens Pregnancy*. 2007;26(2):227-39.

[16] Schaer CA, Schoedon G, Imhof A, Kurrer MO and Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. *Circ Res*. 2006;99(9):943-50.

[17] Åkerström B and Lögdberg L. α_1 -microglobulin. 2006; (Ed.) Åkerström B, Borregaard N, Flower DR and Salier JS. pp. 110-20. Georgetown, TX: Landes Bioscience.

[18] Larsson J, Allhorn M and Åkerström B. The lipocalin α_1 -microglobulin binds heme in different species. *Arch Biochem Biophys*. 2004;432(2):196-204.

[19] Åkerström B, Maghzal GJ, Winterbourn CC and Kettle AJ. The lipocalin α_1 -microglobulin has radical scavenging activity. *J Biol Chem*. 2007;282(43):31493-503.

[20] Olsson MG, Olofsson T, Tapper H and Åkerström B. The lipocalin α_1 -microglobulin protects erythroid K562 cells against oxidative damage induced by heme and reactive oxygen species. *Free Radic Res*. 2008;42(8):725-36.

[21] Larsson J, Wingårdh K, Berggård T, Davies JR, Lögdberg L, Strand SE and Åkerström B. Distribution of iodine 125-labeled α_1 -microglobulin in rats after intravenous injection. *J Lab Clin Med*. 2001;137(3):165-75.

[22] Strober W and Waldmann TA. The role of the kidney in the metabolism of plasma proteins. *Nephron*. 1974;13(1):35-66.

[23] Allhorn M, Berggård T, Nordberg J, Olsson ML and Åkerström B. Processing of the lipocalin α_1 -microglobulin by hemoglobin induces heme-binding and heme-degradation properties. *Blood*. 2002;99(6):1894-901.

[24] Olsson MG, Allhorn M, Olofsson T and Åkerström B. Up-regulation of α_1 -microglobulin by hemoglobin and reactive oxygen species in hepatoma and blood cell lines. *Free Radic Biol Med*. 2007;42(6):842-51.

[25] Schneider H and Huch A. Dual in vitro perfusion of an isolated lobe of human placenta: method and instrumentation. *Contrib Gynecol Obstet*. 1985;13:40-7.

[26] Guller S, Ma Y, Malek A, Di Santo S and Schneider H. Differential release of plasminogen activators during dual perfusion of human placenta: implications in preeclampsia. *Placenta*. 2007;28:278-85.

[27] Di Santo S, Sager R, Andres AC, Guller S and Schneider H. Dual In Vitro Perfusion of an Isolated Cotyledon as a Model to Study the Implication of Changes in the Third Trimester Placenta on Preeclampsia. *Placenta*. 2007;28((Suppl. A)):S23-S32.

[28] Centlow M, Junus K, Nyström H, May K, Larsson I, Olsson MG, Åkerström B, Sager R, Schneider H and Hansson SR. Perfusion of the human placenta with red blood cells and xanthine oxidase mimics preeclampsia in-vitro. *Z Geburtshilfe Neonatol*. 2009;213(3):89-95.

[29] Winterbourn CC. Oxidative reactions of hemoglobin. *Methods Enzymol*. 1990;186:265-72.

[30] Kwasek A, Osmark P, Allhorn M, Lindqvist A, Åkerström B and Wasylewski Z. Production of recombinant human α_1 -microglobulin and mutant forms involved in chromophore formation. *Protein Expr Purif*. 2007;53(1):145-52.

[31] May K, Minarikova V, Linnemann K, Zygmunt M, Kroemer HK, Fusch C and Siegmund W. Role of the multidrug transporter proteins ABCB1 and ABCC2 in the

diaplacental transport of talinolol in the term human placenta. *Drug Metab Dispos.* 2008;36(4):740-4.

[32] Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A and Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. *Genome Biol.* 2002;3(8):SOFTWARE0003.

[33] Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA and Quackenbush J. TM4 microarray software suite. *Methods Enzymol.* 2006;411:134-93.

[34] Greenwood FC, Hunter WM and Glover JS. The Preparation of I-131-Labelled Human Growth Hormone of High Specific Radioactivity. *Biochem J.* 1963;89:114-23.

[35] Åkerström B. Immunological analysis of α_1 -microglobulin in different mammalian and chicken serum. α_1 -Microglobulin is 5-8 kilodaltons larger in primates. *J Biol Chem.* 1985;260(8):4839-44.

[36] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature.* 1970;227(5259):680-5.

[37] Wester L, Johansson MU and Åkerström B. Physicochemical and biochemical characterization of human α_1 -microglobulin expressed in baculovirus-infected insect cells. *Protein Expr Purif.* 1997;11(1):95-103.

[38] Nilson B, Åkerström B and Lögdberg L. Cross-reacting monoclonal anti- α_1 -microglobulin antibodies produced by multi-species immunization and using protein G for the screening assay. *J Immunol Methods.* 1987;99(1):39-45.

[39] Berggård T, Thelin N, Falkenberg C, Enghild JJ and Åkerström B. Prothrombin, albumin and immunoglobulin A form covalent complexes with α_1 -microglobulin in human plasma. *Eur J Biochem.* 1997;245(3):676-83.

[40] Wurz H, Geiger W, Kunzig HJ, Jabs-Lehmann A, Bohn H and Luben G. Radioimmunoassay of SP1 (pregnancy-specific beta1-glycoprotein) in maternal blood and in amniotic fluid normal and pathologic pregnancies. *J Perinat Med.* 1981;9(2):67-78.

[41] Cindrova-Davies T, Yung HW, Johns J, Spasic-Boskovic O, Korolchuk S, Jauniaux E, Burton GJ and Charnock-Jones DS. Oxidative stress, gene expression, and protein changes induced in the human placenta during labor. *Am J Pathol.* 2007;171(4):1168-79.

[42] Sitras V, Paulssen RH, Gronaas H, Vartun A and Acharya G. Gene expression profile in labouring and non-labouring human placenta near term. *Mol Hum Reprod.* 2008;14(1):61-5.

[43] Hempstock J, Bao Y, Bar-Isaac M, Segaren N, Watson A, Charnock-Jones D, Jauniaux E and Burton G. Intralobular differences in antioxidants enzyme expression and activity reflect the pattern of maternal arterial blood flow within the human placenta. *Placenta.* 2003;24:517-23.

[44] de Luca Brunori I, Battini L, Brunori E, Lenzi P, Paparelli A, Simonelli M, Valentino V and Genazzani AR. Placental barrier breakage in preeclampsia: ultrastructural evidence. *Eur J Obstet Gynecol Reprod Biol.* 2005;118(2):182-9.

[45] Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, Charnock-Jones DS and Burton GJ. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. *Am J Pathol.* 2007;170(5):1511-20.

- [46] Buehler PW and D'Agnillo F. Toxicological consequences of extracellular hemoglobin: biochemical and physiological perspectives. *Antioxid Redox Signal*. 2010;12(2):275-91.
- [47] Sood R, Zehnder JL, Druzin ML and Brown PO. Gene expression patterns in human placenta. *Proc Natl Acad Sci U S A*. 2006;103(14):5478-83.
- [48] Hansson SR, Chen Y, Brodzki J, Chen M, Hernandez-Andrade E, Inman JM, Kozhich OA, Larsson I, Marsal K, Medstrand P, Xiang CC and Brownstein MJ. Gene expression profiling of human placentas from preeclamptic and normotensive pregnancies. *Mol Hum Reprod*. 2006;12(3):169-79.
- [49] Enquobahrie DA, Meller M, Rice K, Psaty BM, Siscovick DS and Williams MA. Differential placental gene expression in preeclampsia. *Am J Obstet Gynecol*. 2008;199(5):566 e1-11.
- [50] Allhorn M, Lundqvist K, Schmidtchen A and Åkerström B. Heme-scavenging role of alpha1-microglobulin in chronic ulcers. *J Invest Dermatol*. 2003;121(3):640-6.
- [51] Kaul DK, Liu XD, Chang HY, Nagel RL and Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. *J Clin Invest*. 2004;114(8):1136-45.
- [52] Berggård T, Enghild JJ, Badve S, Salafia CM, Lögdberg L and Åkerström B. Histologic distribution and biochemical properties of α_1 -microglobulin in human placenta. *Am J Reprod Immunol*. 1999;41(1):52-60.
- [53] Polyzos NP, Mauri D, Tsappi M, Tzioras S, Kamposioras K, Cortinovis I and Casazza G. Combined vitamin C and E supplementation during pregnancy for preeclampsia prevention: a systematic review. *Obstet Gynecol Surv*. 2007;62(3):202-6.
- [54] Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, Pearson GD, Wapner RJ, Varner MW, Thorp JM, Jr., Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Smith WJ, Saade G, Sorokin Y and Anderson GB. Vitamins C and E to prevent complications of pregnancy-associated hypertension. *N Engl J Med*. 2010;362(14):1282-91.

Supplementary table 1. Genes with altered gene expression in the group comparisons. The p-value and fold change (within parenthesis) are presented. The fold change is always relative to the second group in the comparison, where a negative value represents decreased gene expression.

| Gene symbol | Gene Name | Medium ↔ Hb | Hb ↔ Hb+A1M | A1M ↔ Hb+A1M |
|-------------|---|-----------------|-------------------|------------------|
| ABCF1 | ATP-BINDING CASSETTE, SUB-FAMILY F (GCN20), MEMBER 1 | | 0.0027 (-1.6) | |
| ACADM | ACYL-COENZYME A DEHYDROGENASE, C-4 TO C-12 STRAIGHT CHAIN | 0.010 (1.6) | | |
| ACLY | ATP CITRATE LYASE | | | 0.0070 (-1.2) |
| ACOT11 | ACYL-COA THIOESTERASE 11 | | 0.0021 (-6.1) | |
| ACOT2 | ACYL-COA THIOESTERASE 2 | 0.0047 (1.9) | 0.0047 (-1.8) | |
| ACSL5 | ACYL-COA SYNTHETASE LONG-CHAIN FAMILY MEMBER 5 | | 0.0036 (-1.9) | |
| ACTG1 | ACTIN, BETA | 0.0096 (1.5) | | |
| ADORA1 | N/A | 0.0026 (2.1) | | |
| ADPRHL2 | ADP-RIBOSYLHYDROLASE LIKE 2 | 0.014 (2.2) | | |
| AFMID | ARYLFORMAMIDASE | 0.0083 (2.4) | | |
| AHNAK | AHNAK NUCLEOPROTEIN (DESMOYOKIN) | | 0.0035 (-3.1) | |
| ALG14 | ASPARAGINE-LINKED GLYCOSYLATION 14 HOMOLOG (YEAST) | | 0.00032 (-1.7) | |
| AMY1B | "AMYLASE, ALPHA 1A; SALIVARY" | 0.011 (2.2) | | |
| ANKMY2 | ANKYRIN REPEAT AND MYND DOMAIN CONTAINING 2 | | | 0.039 (1.4) |
| ANKRD16 | ANKYRIN REPEAT DOMAIN 16 | | | 0.025 (1.9) |
| ANXA8 | ANNEXIN A8 | | | 0.014 (-2.5) |
| APP | AMYLOID BETA (A4) PRECURSOR PROTEIN (PEPTIDASE NEXIN-II, ALZHEIMER DISEASE) | | | 0.041 (-1.6) |
| ARF1 | ADP-RIBOSYLATION FACTOR 1 | | | 0.036 (-1.2) |
| ARF4 | ADP-RIBOSYLATION FACTOR 4 | | 0.0029 (-1.7) | 0.037 (-1.7) |
| ARF4 | ADP-RIBOSYLATION FACTOR 4 | | 0.00014 (-1.6) | 0.040 (-1.5) |
| ARID4B | AT RICH INTERACTIVE DOMAIN 4B (RBP1- LIKE) | | 0.002 (-1.9) | |
| ARL4A | ADP-RIBOSYLATION FACTOR-LIKE 4A | | 0.0013 (-2.2) | |

| | | | | |
|----------|---|-----------------|--------------------|-----------------|
| ARL4A | ADP-RIBOSYLATION FACTOR-LIKE 4A | 0.012 (1.9) | | |
| ARMET | ARGININE-RICH, MUTATED IN EARLY STAGE TUMORS | 0.0041 (1.6) | 0.0014 (-1.7) | |
| ARPC1B | ACTIN RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 1B, 41KDA | 0.0029 (2.3) | | |
| ARSD | ARYLSULFATASE D | | | 0.040 (-1.4) |
| ATE1 | ARGINYLTRANSFERASE 1 | | 0.000099 (-4.5) | |
| ATF1 | ACTIVATING TRANSCRIPTION FACTOR 1 | | | 0.034 (-1.5) |
| ATF3 | ACTIVATING TRANSCRIPTION FACTOR 3 | | 0.0012 (-1.7) | |
| ATG10 | HYPOTHETICAL PROTEIN FLJ13954 | | 0.0031 (-1.8) | |
| ATG4A | ATG4 AUTOPHAGY RELATED 4 HOMOLOG A (S. CEREVISIAE) | 0.0096 (1.8) | | |
| ATP5F1 | ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 COMPLEX, SUBUNIT B1 | 0.012 (1.4) | | |
| ATP5L | ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 COMPLEX, SUBUNIT G | 0.0088 (1.4) | | |
| ATP6V0B | ATPASE, H+ TRANSPORTING, LYSOSOMAL 21KDA, V0 SUBUNIT B | | 0.0012 (-1.5) | |
| AXIIR | SIMILAR TO ANNEXIN II RECEPTOR | 0.0043 (2.1) | | |
| AXIN2 | AXIN 2 (CONDUCTIN, AXIL) | 0.015 (2.6) | | |
| AYP1p1 | N/A | 0.012 (1.6) | | |
| AZI1 | 5-AZACYTIDINE INDUCED 1 | | | 0.021 (1.6) |
| B3GALNT2 | UDP-GALNAC:BETAGLCNAC BETA 1,3-GALACTOSAMINYLTRANSFERASE, POLYPEPTIDE 2 | | | 0.048 (-1.6) |
| B3GNT2 | UDP-GLCNAC:BETAGAL BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 1 | 0.013 (1.7) | | |
| BAG4 | SILENCER OF DEATH DOMAINS | 0.0083 (2.3) | | |
| BMP7 | BONE MORPHOGENETIC PROTEIN 7 (OSTEOGENIC PROTEIN 1) | | | 0.024 (1.3) |
| BNIP1 | BCL2/ADENOVIRUS E1B 19KDA INTERACTING PROTEIN 1 | | 0.0016 (-2.5) | |
| BNIP1 | BCL2/ADENOVIRUS E1B 19KDA INTERACTING PROTEIN 1 | | 0.00053 (-2.4) | |
| BOLA2 | BOLA-LIKE 2 (E. COLI) | 0.0068 (1.8) | | |
| BTBD16 | CHROMOSOME 10 OPEN READING | | 0.0032 | |

| | | | | |
|-----------|---|-----------------|---------------------|-----------------|
| | FRAME 87 | | (-6.5) | |
| BTBD3 | BTB (POZ) DOMAIN CONTAINING 3 | | | 0.018 (1.5) |
| C10orf32 | ARSENIC (+3 OXIDATION STATE) METHYLTRANSFERASE | | 0.00027 (-1.5) | |
| C11orf10 | CHROMOSOME 11 OPEN READING FRAME 10 | | 0.001 (-1.5) | |
| C12orf43 | CHROMOSOME 12 OPEN READING FRAME 43 | | 0.0018 (-1.7) | 0.034 (-1.5) |
| C13orf7 | CHROMOSOME 13 OPEN READING FRAME 7 | | 0.0022 (-1.6) | |
| C14orf122 | CHROMOSOME 14 OPEN READING FRAME 122 | 0.0061 (1.8) | | |
| C14orf151 | CHROMOSOME 14 OPEN READING FRAME 151 | | 0.0023 (-11.2) | |
| C15orf24 | CHROMOSOME 15 OPEN READING FRAME 24 | | 0.00023 (-1.6) | |
| C15orf44 | CHROMOSOME 15 OPEN READING FRAME 44 | | 0.0000078 (-1.7) | |
| C17orf81 | CHROMOSOME 17 OPEN READING FRAME 81 | 0.0051 (2) | | |
| C19orf10 | CHROMOSOME 19 OPEN READING FRAME 10 | 0.0041 (1.5) | | |
| C19orf58 | DDA1 | | | 0.016 (-1.2) |
| C1GALT1 | CORE 1 SYNTHASE, GLYCOPROTEIN-N- ACETYLGALACTOSAMINE 3-BETA- GALACTOSYLTRANSFERASE, 1 | | 0.0048 (-1.5) | 0.011 (-1.5) |
| C1orf198 | CHROMOSOME 1 OPEN READING FRAME 198 | | | 0.0061 (1.7) |
| C1orf77 | CHROMOSOME 1 OPEN READING FRAME 77 | | 0.00019 (-1.5) | |
| C1QB | COMPLEMENT COMPONENT 1, Q SUBCOMPONENT, B CHAIN | | | 0.031 (1.6) |
| C2 | COMPLEMENT COMPONENT 2 | | | 0.031 (1.5) |
| C2orf4 | CHROMOSOME 2 OPEN READING FRAME 4 | 0.0044 (2) | | |
| C3AR1 | COMPLEMENT COMPONENT 3A RECEPTOR 1 | | | 0.023 (3.3) |
| C3orf38 | CHROMOSOME 3 OPEN READING FRAME 38 | 0.0037 (1.6) | | |
| C4orf14 | CHROMOSOME 4 OPEN READING FRAME 14 | 0.0092 (1.5) | | |
| C6orf106 | CHROMOSOME 6 OPEN READING FRAME 106 | | 0.0011 (-4.4) | |
| C6orf166 | CHROMOSOME 6 OPEN READING FRAME 166 | | 0.0029 (-1.6) | |
| C6orf48 | CHROMOSOME 6 OPEN READING FRAME 48 | 0.0055 (1.4) | | |
| C6orf48 | CHROMOSOME 6 OPEN READING | 0.002 | | |

| | | | | |
|----------|---|-----------------|-------------------|------------------|
| | FRAME 48 | (1.6) | | |
| C7orf28B | DKFZP586I1023 PROTEIN | | | 0.033 (-3.2) |
| C9orf58 | CHROMOSOME 9 OPEN READING FRAME 58 | | | 0.035 (2.9) |
| C9orf6 | CHROMOSOME 9 OPEN READING FRAME 6 | 0.0081 (1.7) | | |
| C9orf72 | HYPOTHETICAL PROTEIN FLJ11109 | | | 0.037 (-1.9) |
| CACYBP | CALCYCLIN BINDING PROTEIN | 0.0077 (1.9) | | |
| CASC2 | CANCER SUSCEPTIBILITY CANDIDATE 2 | | | 0.046 (2.1) |
| CASK | CALCIUM/CALMODULIN-DEPENDENT SERINE PROTEIN KINASE (MAGUK FAMILY) | | | 0.042 (3.5) |
| CAV1 | CAVEOLIN 1, CAVEOLAE PROTEIN, 22KDA | 0.0033 (2) | | |
| CAV2 | CAVEOLIN 2 | 0.0033 (2.1) | | |
| CBR1 | CARBONYL REDUCTASE 1 | 0.0054 (1.6) | | |
| CBX3 | CHROMOBOX HOMOLOG 3 (HP1 GAMMA HOMOLOG, DROSOPHILA) | 0.0081 (1.8) | | |
| CCBL2 | KYNURENINE AMINOTRANSFERASE III | | 0.0034 (-1.7) | 0.047 (-1.6) |
| CCDC101 | HYPOTHETICAL PROTEIN BC011981 | | 0.0025 (-1.7) | |
| CCDC104 | SIMILAR TO RIKEN CDNA 4931428D14 GENE | | 0.0043 (-2) | |
| CCDC23 | COILED-COIL DOMAIN CONTAINING 23 | | 0.0021 (-1.6) | |
| CCNB1IP1 | CYCLIN B1 INTERACTING PROTEIN 1 | 0.012 (1.5) | | |
| CDC42EP1 | CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 1 | | | 0.020 (-1.4) |
| CDCA8 | CELL DIVISION CYCLE ASSOCIATED 8 | 0.013 (2) | | |
| CDH1 | CADHERIN 1, TYPE 1, E-CADHERIN (EPITHELIAL) | | | 0.0081 (-1.3) |
| CDK5R1 | CYCLIN-DEPENDENT KINASE 5, REGULATORY SUBUNIT 1 (P35) | | 0.0019 (-8.3) | |
| CDKN2D | CYCLIN-DEPENDENT KINASE INHIBITOR 2D (P19, INHIBITS CDK4) | | 0.0023 (-3) | |
| CGGBP1 | CGG TRIPLET REPEAT BINDING PROTEIN 1 | | | 0.036 (-1.2) |
| CKS2 | CDC28 PROTEIN KINASE REGULATORY SUBUNIT 2 | | | 0.045 (-2.2) |
| CLK3 | CDC-LIKE KINASE 3 | | 0.00057 (-1.7) | |
| CLK3 | CDC-LIKE KINASE 3 | | 0.00096 | |

| | | | | |
|----------|---|-----------------|-------------------|-----------------|
| | | | (-1.6) | |
| CLPP | CLPP CASEINOLYTIC PEPTIDASE, ATP-DEPENDENT, PROTEOLYTIC SUBUNIT HOMOLOG (E. COLI) | | | 0.034 (1.4) |
| CMAS | CYTIDINE MONOPHOSPHATE N-ACETYLNEURAMINIC ACID SYNTHETASE | | | 0.035 (-1.5) |
| CNIH | CORNICHON HOMOLOG (DROSOPHILA) | 0.0057 (1.5) | | |
| COL6A2 | COLLAGEN, TYPE VI, ALPHA 2 | | 0.011 (1.7) | 0.024 (2) |
| COL6A3 | COLLAGEN, TYPE VI, ALPHA 3 | | 0.00026 (1.7) | |
| COL8A2 | COLLAGEN, TYPE VIII, ALPHA 2 | | 0.011 (2.2) | 0.033 (1.4) |
| COMMD5 | COMM DOMAIN CONTAINING 5 | 0.014 (1.5) | | |
| COQ2 | COENZYME Q2 HOMOLOG, PRENYLTRANSFERASE (YEAST) | 0.015 (1.5) | | |
| COX6C | CYTOCHROME C OXIDASE SUBUNIT VIC | | | 0.046 (-1.2) |
| CPM | CARBOXYPEPTIDASE M | 0.012 (2) | 0.008 (-1.7) | |
| CREG1 | CELLULAR REPRESSOR OF E1A-STIMULATED GENES 1 | | | 0.027 (-1.3) |
| CSHL1 | CHORIONIC SOMATOMAMMOTROPIN HORMONE-LIKE 1 | | 0.0016 (-1.7) | |
| CSNK2A1P | CASEIN KINASE 2, ALPHA 1 POLYPEPTIDE PSEUDOGENE | | 0.00022 (-1.5) | |
| CST6 | CYSTATIN E/M | | | 0.0034 (-4) |
| CSTB | CYSTATIN B (STEFIN B) | | 0.002 (-1.7) | |
| CTPS | CTP SYNTHASE | 0.0014 (2.1) | | |
| CXorf38 | CHROMOSOME X OPEN READING FRAME 38 | | 0.0003 (-1.8) | |
| CXorf39 | CHROMOSOME X OPEN READING FRAME 39 | 0.010 (1.6) | | |
| CYP2J2 | CYTOCHROME P450, FAMILY 2, SUBFAMILY J, POLYPEPTIDE 2 | 0.013 (1.5) | | |
| DAAM1 | DISHEVELLED ASSOCIATED ACTIVATOR OF MORPHOGENESIS 1 | | 0.0047 (-1.8) | |
| DAXX | DEATH-ASSOCIATED PROTEIN 6 | | 0.0045 (-1.6) | |
| DBT | DIHYDROLIPOAMIDE BRANCHED CHAIN TRANSACYLASE E2 | 0.011 (1.8) | | |
| DCTN3 | DYNACTIN 3 (P22) | | | 0.024 (-1.2) |
| DDR1 | DISCOIDIN DOMAIN RECEPTOR FAMILY, MEMBER 1 | | | 0.050 (-1.3) |

| | | | | |
|---------------|--|-----------------|--------------------|------------------|
| DDX52 | DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 52 | 0.0036 (1.5) | | |
| DEDD2 | DEATH EFFECTOR DOMAIN CONTAINING 2 | 0.0076 (1.5) | | |
| DERL1 | DER1-LIKE DOMAIN FAMILY, MEMBER 1 | | 0.0023 (-1.6) | |
| DHX9 | DEAH (ASP-GLU-ALA-HIS) BOX POLYPEPTIDE 9 | | 0.00042 (-1.6) | |
| DIMT1L | N/A | 0.0098 (1.7) | | |
| DIP2A | DIP2 DISCO-INTERACTING PROTEIN 2 HOMOLOG A (DROSOPHILA) | | | 0.035 (-1.3) |
| DKFZp434K1815 | HYPOTHETICAL PROTEIN DKFZP434K1815 | | 0.00017 (-1.8) | |
| DNAJA1 | DNAJ (HSP40) HOMOLOG, SUBFAMILY A, MEMBER 1 | 0.010 (1.7) | | |
| DNAJA5 | DNAJ HOMOLOGY SUBFAMILY A MEMBER 5 | | 0.000053 (-7) | 0.026 (-6.1) |
| DNAJB9 | DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 9 | | 0.000037 (-1.7) | |
| DPM2 | DOLICHYL-PHOSPHATE MANNOSYLTRANSFERASE POLYPEPTIDE 2, REGULATORY SUBUNIT | | 0.0002 (-3) | |
| DPP7 | DIPEPTIDYL-PEPTIDASE 7 | | | 0.030 (2.7) |
| DSCAM | DOWN SYNDROME CELL ADHESION MOLECULE | | 0.00077 (-2.1) | |
| DSCR10 | DOWN SYNDROME CRITICAL REGION GENE 10 | | | 0.00066 (1.6) |
| DSCR2 | DOWN SYNDROME CRITICAL REGION GENE 2 | 0.0099 (1.4) | | |
| DVL1 | DISHEVELLED, DSH HOMOLOG 1 (DROSOPHILA) | | | 0.044 (-3.5) |
| DYNLT1 | DYNEIN, LIGHT CHAIN, TCTEX-TYPE 1 | 0.014 (1.5) | | |
| E2F6 | E2F TRANSCRIPTION FACTOR 6 | | 0.0012 (-2) | |
| EBP | EMOPAMIL BINDING PROTEIN (STEROL ISOMERASE) | 0.0034 (1.6) | | |
| EEA1 | EARLY ENDOSOME ANTIGEN 1, 162KD | | 0.00066 (-1.8) | |
| EFNA4 | EPHRIN-A4 | | 0.00018 (-1.7) | |
| EIF2A | EUKARYOTIC TRANSLATION INITIATION FACTOR 2A, 65KDA | | 0.0027 (-1.6) | |
| EIF2S2 | EUKARYOTIC TRANSLATION INITIATION FACTOR 2, SUBUNIT 2 BETA, 38KDA | | 0.00071 (-2) | |
| ELAVL1 | ELAV (EMBRYONIC LETHAL, ABNORMAL VISION, DROSOPHILA)- | | 0.00072 (-10.5) | |

| | | | | |
|----------|--|-----------------|---------------------|-----------------|
| | LIKE 1 (HU ANTIGEN R) | | | |
| ELF2 | E74-LIKE FACTOR 2 (ETS DOMAIN TRANSCRIPTION FACTOR) | | 0.0017 (-5.1) | |
| ELF2 | E74-LIKE FACTOR 2 (ETS DOMAIN TRANSCRIPTION FACTOR) | | 0.0018 (-2.1) | |
| ETFA | ELECTRON-TRANSFER-FLAVOPROTEIN, ALPHA POLYPEPTIDE (GLUTARIC ACIDURIA II) | 0.0085 (1.6) | | |
| ETNK1 | ETHANOLAMINE KINASE 1 | | | 0.040 (-1.6) |
| EXOC1 | EXOCYST COMPLEX COMPONENT 1 | | 0.0000042 (-8.2) | |
| F2R | COAGULATION FACTOR II (THROMBIN) RECEPTOR | | 0.0006 (-1.6) | |
| FAM136A | HYPOTHETICAL PROTEIN FLJ14668 | 0.013 (1.6) | | |
| FAM18B2 | FAMILY WITH SEQUENCE SIMILARITY 18, MEMBER B2 | | 0.00073 (-2.4) | |
| FAM20C | FAMILY WITH SEQUENCE SIMILARITY 20, MEMBER C | | | 0.0086 (1.7) |
| FAM36A | FAMILY WITH SEQUENCE SIMILARITY 36, MEMBER A | | | 0.014 (-1.3) |
| FAM3C | FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER C | | | 0.040 (-1.7) |
| FAM83B | CHROMOSOME 6 OPEN READING FRAME 143 | | 0.0031 (-3) | 0.019 (-2.8) |
| FBLN1 | FIBULIN 1 | | 0.0033 (-1.8) | 0.021 (-2) |
| FBXO5 | F-BOX PROTEIN 5 | 0.012 (1.6) | | |
| FCGR1A | FC FRAGMENT OF IGG, HIGH AFFINITY IA, RECEPTOR (CD64) | 0.0057 (2.8) | | |
| FCGR1B | FC FRAGMENT OF IGG, HIGH AFFINITY IB, RECEPTOR (CD64) | 0.0074 (2) | | |
| FCGR1B | FC FRAGMENT OF IGG, HIGH AFFINITY IB, RECEPTOR (CD64) | 0.0073 (2.5) | | |
| FGFR3 | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (ACHONDROPLASIA, THANATOPHORIC DWARFISM) | | | 0.038 (1.9) |
| FKBP1A | FK506 BINDING PROTEIN 1A, 12KDA | | 0.0035 (-2) | |
| FLJ10769 | HYPOTHETICAL PROTEIN LOC51254 | | 0.002 (-1.8) | |
| FLJ12078 | HYPOTHETICAL PROTEIN FLJ12078 | | 0.0024 (-3.8) | 0.045 (-3.2) |
| FLJ12716 | FLJ12716 PROTEIN | | 0.00047 (1.8) | |
| FLJ20035 | HYPOTHETICAL PROTEIN FLJ10787 | | 0.0047 (-2.6) | |
| FLJ22222 | HYPOTHETICAL PROTEIN FLJ22222 | | 0.0043 (-2) | |

| | | | | |
|-----------|--|-----------------|--------------------|-----------------|
| FLJ33790 | HYPOTHETICAL PROTEIN FLJ33790 | | 0.0038 (-2.8) | |
| FLJ43663 | HYPOTHETICAL PROTEIN FLJ43663 | | 0.0022 (-1.6) | |
| FLJ46838 | FLJ46838 PROTEIN | | | 0.023 (-1.5) |
| FLJ90709 | HYPOTHETICAL PROTEIN FLJ90709 | 0.012 (1.5) | | |
| FTL | FERRITIN, LIGHT POLYPEPTIDE | | 0.00065 (-1.6) | |
| FTSJ3 | HYPOTHETICAL PROTEIN FLJ20062 | | | 0.029 (-2.5) |
| GABARAPL2 | GABA(A) RECEPTOR-ASSOCIATED PROTEIN-LIKE 2 | | 0.00024 (1.9) | |
| GAST | GASTRIN | | 0.0032 (-2.3) | |
| GCA | GRANCALCIN, EF-HAND CALCIUM BINDING PROTEIN | 0.0051 (1.6) | | |
| GDAP2 | GANGLIOSIDE INDUCED DIFFERENTIATION ASSOCIATED PROTEIN 2 | | 0.00016 (-3.7) | |
| GDF15 | GROWTH DIFFERENTIATION FACTOR 15 | | 0.000022 (-1.6) | 0.023 (-1.3) |
| GFM2 | G ELONGATION FACTOR, MITOCHONDRIAL 2 | | 0.00046 (-3) | |
| GJA5 | GAP JUNCTION PROTEIN, ALPHA 5, 40KDA (CONNEXIN 40) | 0.010 (2) | 0.015 (-1.9) | |
| GLMN | GLOMULIN, FKBP ASSOCIATED PROTEIN | | 0.0039 (-1.5) | |
| GLYCKT | CG9886-LIKE | | 0.0016 (-2.1) | |
| GPBP1 | GC-RICH PROMOTER BINDING PROTEIN 1 | | 0.0021 (-1.7) | |
| GPBP1L1 | GC-RICH PROMOTER BINDING PROTEIN 1-LIKE 1 | | 0.00016 (-1.7) | |
| GPC6 | GLYPICAN 6 | | 0.00024 (-2.6) | |
| GPR37 | G PROTEIN-COUPLED RECEPTOR 37 (ENDOTHELIN RECEPTOR TYPE B-LIKE) | | 0.0029 (-2.6) | |
| GPR89C | G PROTEIN-COUPLED RECEPTOR 89A | 0.0061 (1.7) | | |
| GRHL1 | GRAINYHEAD-LIKE 1 (DROSOPHILA) | | 0.0023 (-2.2) | |
| GTF2I | GENERAL TRANSCRIPTION FACTOR II, I | 0.0052 (1.4) | | |
| GTF2IRD1 | GTF2I REPEAT DOMAIN CONTAINING 1 | | | 0.042 (2.7) |
| GTF2IRD2 | GTF2I REPEAT DOMAIN CONTAINING 2 | | 0.0014 (-2.3) | |
| H19 | H19, IMPRINTED MATERNALLY EXPRESSED UNTRANSLATED MRNA | | | 0.020 (-1.2) |

| | | | | |
|------------|--|-----------------|--------------------|-----------------|
| HACL1 | PHYTANOYL-COA 2-HYDROXYLASE 2 | | 0.000043 (-1.5) | |
| HAVCR2 | HEPATITIS A VIRUS CELLULAR RECEPTOR 2 | 0.015 (1.7) | | |
| HAX1 | HCLS1 ASSOCIATED PROTEIN X-1 | 0.0063 (1.7) | | |
| HEATR2 | HYPOTHETICAL PROTEIN FLJ20397 | 0.010 (2.1) | | |
| HEATR3 | HYPOTHETICAL PROTEIN FLJ20718 | | | 0.024 (-3.1) |
| HELLS | HELICASE, LYMPHOID-SPECIFIC | | | 0.018 (-1.6) |
| HERPUD1 | HOMOCYSTEINE-INDUCIBLE, ENDOPLASMIC RETICULUM STRESS-INDUCIBLE, UBIQUITIN-LIKE DOMAIN MEMBER 1 | 0.015 (1.4) | 0.0011 (-1.9) | |
| HIGD1A | HIG1 DOMAIN FAMILY, MEMBER 1A | | | 0.027 (-1.5) |
| HIGD1A | HIG1 DOMAIN FAMILY, MEMBER 1A | | 0.00059 (-1.6) | |
| HIST1H3A | HISTONE 1, H3A | | | 0.024 (-3.4) |
| HIST1H4K | H4 HISTONE, FAMILY 2 | 0.010 (2.5) | | |
| HIST2H2AA3 | HISTONE 2, H2AA | | 0.0023 (-1.6) | |
| HIST2H2AC | HISTONE 2, H2AC | | 0.00063 (-1.7) | |
| HNRPK | HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K | | 0.0016 (-1.6) | |
| HPS5 | HERMANSKY-PUDLAK SYNDROME 5 | 0.014 (1.6) | | |
| HSCB | J-TYPE CO-CHAPERONE HSC20 | 0.014 (1.6) | | |
| HSP90AA1 | HEAT SHOCK PROTEIN 90KDA ALPHA (CYTOSOLIC), CLASS A MEMBER 1 | 0.0097 (1.6) | 0.00051 (-2.1) | |
| HSP90B1 | HEAT SHOCK PROTEIN 90KDA BETA (GRP94), MEMBER 1 | | 0.0017 (-1.5) | |
| HSPC171 | HSPC171 PROTEIN | | | 0.041 (-1.2) |
| HSPE1 | HEAT SHOCK 10KDA PROTEIN 1 (CHAPERONIN 10) | 0.013 (1.6) | | |
| HSPH1 | HEAT SHOCK 105KDA/110KDA PROTEIN 1 | 0.0069 (2.6) | | |
| HSZFP36 | ZFP-36 FOR A ZINC FINGER PROTEIN | | 0.00038 (-1.9) | |
| HTRA2 | HTRA SERINE PEPTIDASE 2 | 0.0083 (1.8) | | |
| ICA1 | ISLET CELL AUTOANTIGEN 1, 69KDA | | | 0.019 (-1.7) |
| ICAM3 | INTERCELLULAR ADHESION | 0.0074 | | |

| | | | | |
|----------|---|-----------------|-------------------|-----------------|
| | MOLECULE 3 | (2.3) | | |
| IFITM2 | INTERFERON INDUCED TRANSMEMBRANE PROTEIN 2 (1-8D) | 0.0063 (1.6) | | |
| IFITM3 | INTERFERON INDUCED TRANSMEMBRANE PROTEIN 3 (1-8U) | 0.0088 (1.6) | | |
| IFNGR1 | INTERFERON GAMMA RECEPTOR 1 | | 0.004 (-1.6) | |
| IFRG15 | INTERFERON RESPONSIVE GENE 15 | | 0.0024 (-1.6) | |
| IIP45 | INVASION INHIBITORY PROTEIN 45 | | 0.0019 (-1.7) | |
| INPP5F | N/A | 0.0039 (2.8) | | |
| IRF6 | INTERFERON REGULATORY FACTOR 6 | 0.0035 (2.4) | | |
| ITIH5 | INTER-ALPHA (GLOBULIN) INHIBITOR H5 | | 0.003 (-1.6) | |
| ITM2B | INTEGRAL MEMBRANE PROTEIN 2B | | | 0.026 (-1.4) |
| ITM2C | INTEGRAL MEMBRANE PROTEIN 2C | 0.0073 (2.1) | 0.014 (-1.7) | |
| KCNMB4 | POTASSIUM LARGE CONDUCTANCE CALCIUM-ACTIVATED CHANNEL, SUBFAMILY M, BETA MEMBER 4 | | | 0.039 (3.3) |
| KHDRBS3 | KH DOMAIN CONTAINING, RNA BINDING, SIGNAL TRANSDUCTION ASSOCIATED 3 | | | 0.028 (-2.9) |
| KIAA0427 | KIAA0427 | | | 0.0085 (2.7) |
| KIAA1276 | KIAA1276 PROTEIN | | | 0.036 (-7) |
| KREMEN1 | KRINGLE CONTAINING TRANSMEMBRANE PROTEIN 1 | 0.0039 (1.4) | | |
| KRT19 | KERATIN 19 | | 0.0016 (-1.7) | |
| KRT27 | KERATIN 25C | | | 0.020 (-2.3) |
| KRT86 | KERATIN, HAIR, BASIC, 1 | | | 0.019 (2) |
| KRTCAP2 | KERATINOCYTE ASSOCIATED PROTEIN 2 | | 0.00031 (-1.5) | |
| Kua-UEV | UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 1 | | 0.0022 (-2) | |
| KYNU | KYNURENINASE (L-KYNURENINE HYDROLASE) | | 0.000038 (-2) | 0.013 (-1.7) |
| LACTB | HYPOTHETICAL PROTEIN FLJ14902 | | 0.0038 (-3.1) | |
| LAMA4 | LAMININ, ALPHA 4 | | 0.0016 (1.9) | |
| LATS1 | LATS, LARGE TUMOR SUPPRESSOR, HOMOLOG 1 (DROSOPHILA) | | | 0.050 (-3.6) |

| | | | | |
|-----------|---|-----------------|-------------------|-----------------|
| LIAS | LIPOIC ACID SYNTHETASE | 0.0099 (1.9) | | |
| LOC153222 | ADULT RETINA PROTEIN | | 0.0034 (-2.4) | |
| LOC162073 | HYPOTHETICAL PROTEIN LOC162073 | | 0.0046 (-1.9) | |
| LOC220686 | HYPOTHETICAL PROTEIN LOC220686 | | 0.0013 (-1.6) | |
| LOC341457 | SIMILAR TO PEPTIDYLPROLYL ISOMERASE A ISOFORM 1 | 0.013 (1.5) | | |
| LOC347544 | SIMILAR TO RIBOSOMAL PROTEIN L18A | 0.012 (1.6) | | |
| LOC387820 | SIMILAR TO DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 6 ISOFORM A | | 0.0048 (-1.6) | |
| LOC387841 | SIMILAR TO RIBOSOMAL PROTEIN L13A | | | 0.011 (-1.2) |
| LOC387921 | HYPOTHETICAL PROTEIN LOC283506 | | 0.00041 (-2.7) | |
| LOC388654 | SIMILAR TO LAMININ RECEPTOR 1 (RIBOSOMAL PROTEIN SA) | 0.0018 (1.5) | | |
| LOC388948 | HYPOTHETICAL GENE SUPPORTED BY BC062774 | | 0.0041 (-2) | |
| LOC389286 | SIMILAR TO FKSG62 | | 0.0014 (-2.4) | |
| LOC389517 | *no* | | | 0.049 (-6.9) |
| LOC389517 | N/A | | | 0.043 (-5.5) |
| LOC390354 | N/A | 0.0041 (1.6) | | |
| LOC402694 | SIMILAR TO RIBOSOMAL PROTEIN L15 | 0.0093 (1.4) | | |
| LOC441050 | SIMILAR TO UNACTIVE PROGESTERONE RECEPTOR, 23 KD | 0.004 (1.9) | | |
| LOC442454 | UBIQUINOL-CYTOCHROME C REDUCTASE BINDING PROTEIN PSEUDOGENE | | | 0.038 (-1.2) |
| LOC51136 | PTD016 PROTEIN | 0.011 (1.9) | | |
| LOC642033 | SIMILAR TO ATP-BINDING CASSETTE, SUB-FAMILY F, MEMBER 1 ISOFORM B | | 0.0016 (-2.2) | |
| LOC642236 | SIMILAR TO FRG1 PROTEIN (FSHD REGION GENE 1 PROTEIN) | 0.014 (2.3) | | |
| LOC642299 | HYPOTHETICAL PROTEIN LOC642299 | | | 0.031 (-1.3) |
| LOC642299 | HYPOTHETICAL PROTEIN LOC642299 | | 0.0022 (-1.6) | |
| LOC642393 | SIMILAR TO MITOCHONDRIAL RIBOSOMAL PROTEIN L20 | | | 0.0035 (-3) |
| LOC643035 | SIMILAR TO CG33096-PB, ISOFORM B | | 0.00028 (1.8) | |

| | | | | |
|-----------|---|-----------------|----------------------|-----------------|
| LOC643433 | SIMILAR TO 60S RIBOSOMAL PROTEIN L29 (CELL SURFACE HEPARIN BINDING PROTEIN HIP) | 0.006 (1.5) | | |
| LOC644033 | SIMILAR TO SIMILAR TO RPL23AP7 PROTEIN | 0.0071 (1.5) | | |
| LOC644584 | SIMILAR TO RNA-BINDING PROTEIN EWS | | 0.00002 (-2.9) | |
| LOC644634 | HYPOTHETICAL PROTEIN LOC644634 | | 0.0017 (1.7) | |
| LOC645261 | HYPOTHETICAL PROTEIN LOC645261 | | 0.0041 (-2.1) | |
| LOC647108 | HYPOTHETICAL PROTEIN LOC647108 | 0.010 (2.2) | | |
| LOC647197 | HYPOTHETICAL PROTEIN LOC647197 | | 0.0036 (-2.7) | |
| LOC647784 | HYPOTHETICAL PROTEIN LOC647784 | | | 0.010 (4.4) |
| LOC649049 | SIMILAR TO ACIDIC RIBOSOMAL PHOSPHOPROTEIN P0 | 0.0082 (1.5) | | |
| LOC649150 | SIMILAR TO EUKARYOTIC TRANSLATION ELONGATION FACTOR 1 ALPHA 2 | | 0.00000031 (-1.5) | |
| LOC649447 | SIMILAR TO 60S RIBOSOMAL PROTEIN L29 (CELL SURFACE HEPARIN BINDING PROTEIN HIP) | 0.012 (1.5) | | |
| LOC649555 | SIMILAR TO EUKARYOTIC TRANSLATION INITIATION FACTOR 4E | 0.0071 (1.6) | | |
| LOC651429 | HYPOTHETICAL PROTEIN LOC651429 | | 0.0041 (-2.5) | |
| LOC651576 | SIMILAR TO TUBULIN, ALPHA 8 LIKE | | 0.0014 (-8.1) | 0.029 (-5) |
| LOC652844 | SIMILAR TO PHOSPHODIESTERASE 4D INTERACTING PROTEIN ISOFORM 2 | | 0.0045 (-2.9) | |
| LOC652846 | SIMILAR TO ANNEXIN A8 (ANNEXIN VIII) (VASCULAR ANTICOAGULANT-BETA) (VAC-BETA) | | | 0.049 (-2.1) |
| LOC652864 | SIMILAR TO MITOCHONDRIAL IMPORT INNER MEMBRANE TRANSLOCASE SUBUNIT TIM23 | 0.014 (1.6) | | |
| LOC653232 | SIMILAR TO RIBOSOMAL PROTEIN L15 | 0.0088 (1.5) | | |
| LOC653489 | SIMILAR TO RAN-BINDING PROTEIN 2 (RANBP2) (NUCLEAR PORE COMPLEX PROTEIN NUP358) (NUCLEOPORIN NUP358) (358 KDA NUCLEOPORIN) (P270) | | 0.0011 (-8) | |
| LOC653505 | SIMILAR TO PEPTIDYLPROLYL ISOMERASE A (CYCLOPHILIN A)-LIKE 4 | 0.0068 (1.7) | | |
| LOC653566 | SIMILAR TO SIGNAL PEPTIDASE COMPLEX SUBUNIT 2 (MICROSOMAL SIGNAL PEPTIDASE 25 KDA SUBUNIT) | | 0.0000074 (-1.5) | 0.040 (-1.3) |

| | | | | |
|-----------|--|------------------|-------------------|-----------------|
| | (SPASE 25 KDA SUBUNIT) | | | |
| LOC653629 | SIMILAR TO WILLIAMS BEUREN SYNDROME CHROMOSOME REGION 19 | | | 0.030 (-5.1) |
| LOC654074 | SIMILAR TO HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN C ISOFORM B | | 0.004 (1.7) | |
| LOC654174 | SIMILAR TO CG4775-PA | | 0.00014 (-3.1) | |
| LOC728492 | SMALL EDRK-RICH FACTOR 1A (TELOMERIC) | 0.007 (1.6) | 0.0019 (-2.2) | |
| LOC728739 | N/A | 0.014 (1.4) | | |
| LOC730256 | *no* | | 0.0039 (-1.9) | |
| LOC84661 | DPY-30-LIKE PROTEIN | 0.011 (1.5) | | |
| LRP1 | LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 1 (ALPHA-2-MACROGLOBULIN RECEPTOR) | | | 0.029 (3.2) |
| LRRN3 | LEUCINE RICH REPEAT NEURONAL 3 | | 0.0016 (-3.1) | |
| LSM1 | LSM1 HOMOLOG, U6 SMALL NUCLEAR RNA ASSOCIATED (S. CEREVISIAE) | 0.0052 (1.5) | | |
| MAD2L2 | MAD2 MITOTIC ARREST DEFICIENT-LIKE 2 (YEAST) | | | 0.036 (-1.6) |
| MAGEL2 | MAGE-LIKE 2 | 0.013 (2.2) | | |
| MALL | MAL, T-CELL DIFFERENTIATION PROTEIN-LIKE | | | 0.015 (-2.3) |
| MAP7D3 | HYPOTHETICAL PROTEIN FLJ12649 | 0.0099 (-1.8) | | |
| MAPK1 | MITOGEN-ACTIVATED PROTEIN KINASE 1 | 0.0058 (1.8) | | |
| MAPRE3 | MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY, MEMBER 3 | 0.013 (-1.5) | | |
| MAX | MYC ASSOCIATED FACTOR X | | | 0.038 (12.6) |
| MBD2 | METHYL-CPG BINDING DOMAIN PROTEIN 2 | | 0.0043 (-1.9) | |
| MBTD1 | MBT DOMAIN CONTAINING 1 | | | 0.021 (1.4) |
| MCART1 | MITOCHONDRIAL CARRIER TRIPLE REPEAT 1 | | 0.0013 (-5.9) | |
| MDM2 | MDM2, TRANSFORMED 3T3 CELL DOUBLE MINUTE 2, P53 BINDING PROTEIN (MOUSE) | | 0.0038 (-7.6) | |
| ME2 | MALIC ENZYME 2, NAD(+)-DEPENDENT, MITOCHONDRIAL | 0.0079 (1.6) | | |
| MELK | MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | 0.0088 (1.6) | | |

| | | | | |
|----------|---|-----------------|-------------------|-----------------|
| METTL9 | DORA REVERSE STRAND PROTEIN 1 | | 0.0017 (-1.8) | 0.039 (-1.8) |
| MGC3731 | HYPOTHETICAL PROTEIN MGC3731 | 0.005 (1.7) | | |
| MGC7036 | HYPOTHETICAL PROTEIN MGC7036 | | | 0.050 (-1.2) |
| MGC72104 | SIMILAR TO FRG1 PROTEIN (FSHD REGION GENE 1 PROTEIN) | 0.010 (1.9) | | |
| MIB2 | MINDBOMB HOMOLOG 2 (DROSOPHILA) | | 0.00012 (-1.7) | 0.041 (-1.5) |
| MLLT11 | "MYELOID/LYMPHOID OR MIXED-LINEAGE LEUKEMIA (TRITHORAX HOMOLOG, DROSOPHILA); TRANSLOCATED TO, 11" | | | 0.030 (-1.5) |
| MOBKL2C | MOB1, MPS ONE BINDER KINASE ACTIVATOR-LIKE 2C (YEAST) | | 0.0011 (-1.9) | |
| MORC4 | MORC FAMILY CW-TYPE ZINC FINGER 4 | | 0.00016 (1.7) | |
| MORN2 | MORN REPEAT CONTAINING 2 | | 0.00022 (-2.4) | |
| MRPL22 | MITOCHONDRIAL RIBOSOMAL PROTEIN L22 | 0.0099 (1.6) | | |
| MRPL32 | MITOCHONDRIAL RIBOSOMAL PROTEIN L32 | 0.013 (1.5) | | |
| MRPL44 | MITOCHONDRIAL RIBOSOMAL PROTEIN L44 | 0.010 (1.4) | | |
| MRPS9 | MITOCHONDRIAL RIBOSOMAL PROTEIN S9 | 0.0016 (1.9) | | |
| MTG1 | MITOCHONDRIAL GTPASE 1 HOMOLOG (S. CEREVISIAE) | | 0.00074 (-5.5) | |
| MTMR11 | MYOTUBULARIN RELATED PROTEIN 11 | | 0.0041 (-1.8) | |
| MTP18 | MITOCHONDRIAL PROTEIN 18 KDA | 0.012 (1.6) | | |
| MTP18 | MITOCHONDRIAL PROTEIN 18 KDA | 0.011 (2.5) | | |
| MTRR | 5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE METHYLTRANSFERASE REDUCTASE | 0.0066 (1.8) | | |
| MYL6B | MYOSIN LIGHT CHAIN 1 SLOW A | 0.012 (1.8) | | |
| MYL9 | MYOSIN, LIGHT POLYPEPTIDE 9, REGULATORY | | | 0.0085 (3.4) |
| MYO18A | TGFB1-INDUCED ANTI-APOPTOTIC FACTOR 1 | | | 0.015 (3.2) |
| NA | N/A | | | 0.028 (-4.5) |
| NA | N/A | | | 0.042 (-3.3) |
| NA | N/A | | | 0.031 (-2.9) |

| | | | | |
|--------|--|-----------------|---------------------|-----------------|
| NA | N/A | | | 0.028 (-2.3) |
| NA | N/A | | | 0.048 (-2) |
| NA | HYPOTHETICAL PROTEIN LOC150837 | | | 0.030 (-2) |
| NA | N/A | | | 0.045 (-1.3) |
| NA | N/A | | | 0.028 (1.9) |
| NA | N/A | | | 0.029 (2.3) |
| NA | HYPOTHETICAL PROTEIN LOC121838 | | | 0.016 (3.3) |
| NA | N/A | | | 0.041 (3.8) |
| NA | N/A | | 0.00075 (-8.4) | |
| NA | N/A | | 0.0016 (-5.6) | |
| NA | N/A | | 0.0015 (-4.2) | |
| NA | N/A | | 0.0029 (-4) | |
| NA | N/A | | 0.0029 (-2.5) | |
| NA | N/A | | 0.0005 (-2.5) | |
| NA | N/A | | 0.0015 (-2.4) | |
| NA | HYPOTHETICAL PROTEIN LOC150837 | | 0.00084 (-1.8) | |
| NA | N/A | 0.0023 (2) | | |
| NAG18 | NAG18 PROTEIN | | 0.0000027 (-1.5) | |
| NARG2 | NMDA RECEPTOR REGULATED 2 | | 0.0012 (-3.4) | |
| NCAPH2 | KLEISIN BETA | | | 0.031 (1.8) |
| NCF4 | NEUTROPHIL CYTOSOLIC FACTOR 4, 40KDA | 0.0021 (1.6) | | |
| NEDD9 | NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWN- REGULATED 9 | | 0.0008 (-3.5) | |
| NET1 | NEUROEPITHELIAL CELL TRANSFORMING GENE 1 | | 0.0033 (-1.7) | |
| NEXN | NEXILIN (F ACTIN BINDING PROTEIN) | 0.0081 (3.8) | | |
| NFIX | NUCLEAR FACTOR I/X (CCAAT- BINDING TRANSCRIPTION FACTOR) | | 0.000011 (2.9) | |

| | | | | |
|---------|---|-----------------|-------------------|------------------|
| NFKBIE | NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B-CELLS INHIBITOR, EPSILON | | 0.0024 (-3.2) | |
| NFYA | NUCLEAR TRANSCRIPTION FACTOR Y, ALPHA | | 0.0019 (-2) | |
| NKIRAS1 | NFKB INHIBITOR INTERACTING RAS-LIKE 1 | | 0.0015 (-1.7) | |
| NOC3L | NUCLEOLAR COMPLEX ASSOCIATED 3 HOMOLOG (S. CEREVISIAE) | 0.013 (1.7) | | |
| NOL14 | CHROMOSOME 4 OPEN READING FRAME 9 | 0.0071 (1.5) | | |
| NOL5A | NUCLEOLAR PROTEIN 5A (56KDA WITH KKE/D REPEAT) | 0.014 (1.7) | | |
| NP | NUCLEOSIDE PHOSPHORYLASE | 0.011 (1.7) | | |
| NPM3 | NUCLEOPHOSMIN/NUCLEOPLASMIN, 3 | 0.011 (1.6) | | |
| NPSR1 | G PROTEIN-COUPLED RECEPTOR 154 | 0.013 (1.7) | | |
| NRBP2 | NUCLEAR RECEPTOR BINDING PROTEIN 2 | | 0.0018 (1.9) | |
| NSDHL | NAD(P) DEPENDENT STEROID DEHYDROGENASE-LIKE | 0.012 (1.8) | | |
| NSL1 | CHROMOSOME 1 OPEN READING FRAME 48 | 0.0092 (1.6) | | |
| NSUN5 | NOL1/NOP2/SUN DOMAIN FAMILY, MEMBER 5 | | 0.0047 (-4.4) | |
| NUMA1 | NUCLEAR MITOTIC APPARATUS PROTEIN 1 | | 0.00006 (1.7) | |
| NUP35 | NUCLEOPORIN 35KDA | 0.011 (2) | | |
| ODC1 | ORNITHINE DECARBOXYLASE 1 | | 0.00054 (-2.2) | |
| OR8H3 | OLFACTORY RECEPTOR, FAMILY 8, SUBFAMILY H, MEMBER 3 | | 0.0032 (2) | |
| ORC6L | ORIGIN RECOGNITION COMPLEX, SUBUNIT 6 HOMOLOG-LIKE (YEAST) | 0.0025 (2.4) | | |
| OSBPL11 | HYPOTHETICAL PROTEIN FLJ13164 | | | 0.011 (1.6) |
| OSBPL1A | OXYSTEROL-BINDING PROTEIN-RELATED PROTEIN 1 | | | 0.0097 (-2.4) |
| OSBPL1A | OXYSTEROL-BINDING PROTEIN-RELATED PROTEIN 1 | 0.0013 (3.5) | | |
| OSTF1 | OSTEOCLAST STIMULATING FACTOR 1 | | 0.001 (-1.5) | |
| PABPC1 | POLY(A) BINDING PROTEIN, CYTOPLASMIC 2 | | 0.0021 (-1.6) | |
| PAK1IP1 | PAK1 INTERACTING PROTEIN 1 | | 0.0025 (-2) | |
| PARP3 | POLY (ADP-RIBOSE) POLYMERASE FAMILY, MEMBER 3 | 0.0078 (2.4) | | |

| | | | | |
|---------|--|-----------------|-------------------|-----------------|
| PCDH10 | PROTODADHERIN 10 | | | 0.034 (2.6) |
| PDCD10 | PROGRAMMED CELL DEATH 10 | 0.0043 (1.8) | | |
| PDCL3 | PHOSDUCIN-LIKE 3 | 0.015 (1.9) | | |
| PDE4C | PHOSPHODIESTERASE 4C, CAMP-SPECIFIC (PHOSPHODIESTERASE E1 DUNCE HOMOLOG, DROSOPHILA) | | | 0.043 (-1.3) |
| PDGFRL | PLATELET-DERIVED GROWTH FACTOR RECEPTOR-LIKE | | 0.0016 (-2.2) | |
| PDLIM3 | PDZ AND LIM DOMAIN 3 | 0.014 (1.8) | | |
| PDLIM5 | PDZ AND LIM DOMAIN 5 | | 0.00085 (-3) | |
| PEA15 | PHOSPHOPROTEIN ENRICHED IN ASTROCYTES 15 | | 0.0039 (-1.5) | |
| PELO | PRO1770 PROTEIN | 0.0053 (1.6) | | |
| PFDN6 | PREFOLDIN SUBUNIT 6 | | 0.0036 (-2) | |
| PGM5 | PHOSPHOGLUCOMUTASE 5 | | | 0.048 (2.6) |
| PIGC | N/A | 0.0052 (1.6) | | |
| PIK3C3 | PHOSPHOINOSITIDE-3-KINASE, CLASS 3 | | 0.00081 (2.3) | |
| PITPNM2 | PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, MEMBRANE-ASSOCIATED 2 | | | 0.040 (1.6) |
| PITX1 | PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 1 | | | 0.022 (2.4) |
| PKD1 | POLYCYSTIC KIDNEY DISEASE 1 (AUTOSOMAL DOMINANT) | | | 0.042 (3.9) |
| PLEKHB2 | PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, FAMILY B (EVECTINS) MEMBER 2 | | 0.0033 (-1.8) | |
| PODXL | PODOCALYXIN-LIKE | | 0.00098 (2.2) | |
| POLB | POLYMERASE (DNA DIRECTED), BETA | 0.011 (1.6) | | |
| POLD3 | POLYMERASE (DNA-DIRECTED), DELTA 3, ACCESSORY SUBUNIT | | 0.00091 (-3.9) | |
| POLDIP2 | POLYMERASE (DNA-DIRECTED), DELTA INTERACTING PROTEIN 2 | | 0.0023 (-1.8) | |
| POLR2K | POLYMERASE (RNA) II (DNA DIRECTED) POLYPEPTIDE K, 7.0KDA | | | 0.046 (2.8) |
| POLR3D | POLYMERASE (RNA) III (DNA DIRECTED) POLYPEPTIDE D, 44KDA | | 0.00043 (-2.5) | |
| PPA1 | N/A | 0.011 (1.6) | | |
| PPARG | PEROXISOME PROLIFERATIVE | | | 0.011 |

| | | | | |
|----------|---|---------------|-----------------|--------------|
| | ACTIVATED RECEPTOR, GAMMA | | | (-1.5) |
| PPIG | PEPTIDYLPROLYL ISOMERASE G (CYCLOPHILIN G) | | 0.000051 (-1.6) | |
| PPL | PERIPLAKIN | | | 0.011 (1.9) |
| PPP1R14B | PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 14B | | 0.0023 (-1.6) | |
| PPP2CB | PROTEIN PHOSPHATASE 2 (FORMERLY 2A), CATALYTIC SUBUNIT, ALPHA ISOFORM | | 0.00068 (-9.7) | |
| PPP3R1 | PROTEIN PHOSPHATASE 3 (FORMERLY 2B), REGULATORY SUBUNIT B, 19KDA, ALPHA ISOFORM (CALCINEURIN B, TYPE I) | | 0.0048 (-1.5) | |
| PQLC3 | PQ LOOP REPEAT CONTAINING 3 | | | 0.041 (-1.9) |
| PQLC3 | PQ LOOP REPEAT CONTAINING 3 | | 0.0036 (-2) | |
| PRDM6 | PR DOMAIN CONTAINING 6 | | 0.0028 (5.4) | |
| PRG2 | PROTEOGLYCAN 2, BONE MARROW (NATURAL KILLER CELL ACTIVATOR, EOSINOPHIL GRANULE MAJOR BASIC PROTEIN) | | 0.0024 (-6.9) | |
| PRKAG1 | N/A | 0.014 (1.5) | | |
| PROM1 | PROMININ 1 | | | 0.029 (1.4) |
| PRRG4 | PROLINE RICH GLA (G-CARBOXYGLUTAMIC ACID) 4 (TRANSMEMBRANE) | | 0.0028 (1.9) | |
| PSG3 | PREGNANCY SPECIFIC BETA-1-GLYCOPROTEIN 3 | 0.0095 (-1.2) | | |
| PSG4 | PREGNANCY SPECIFIC BETA-1-GLYCOPROTEIN 4 | | 0.0046 (-1.7) | |
| PSG7 | PREGNANCY SPECIFIC BETA-1-GLYCOPROTEIN 2 | 0.010 (-1.3) | | |
| PSG9 | PREGNANCY SPECIFIC BETA-1-GLYCOPROTEIN 9 | | 0.000016 (-1.7) | |
| PSMA4 | PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, ALPHA TYPE, 4 | 0.0028 (1.6) | | |
| PSMB8 | PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, BETA TYPE, 8 (LARGE MULTIFUNCTIONAL PEPTIDASE 7) | 0.0092 (2.5) | | |
| PSMB8 | PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, BETA TYPE, 8 (LARGE MULTIFUNCTIONAL PEPTIDASE 7) | 0.0088 (2.7) | | |

| | | | | |
|---------|---|-----------------|---------------------|-----------------|
| PSMD13 | PROTEASOME (PROSOME, MACROPAIN) 26S SUBUNIT, NON-ATPASE, 13 | | 0.0028 (2.5) | |
| PTHR1 | PARATHYROID HORMONE RECEPTOR 1 | | | 0.023 (1.8) |
| PTMA | PROTHYMOSIN, ALPHA (GENE SEQUENCE 28) | | 0.0041 (1.7) | |
| PTPN2 | PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2 | | 0.00012 (-3.2) | |
| PTPRA | PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, A | | | 0.0032 (1.4) |
| PTPRA | PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, A | | 0.0048 (-1.7) | |
| PTS | 6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE | 0.0066 (1.7) | 0.0032 (-1.7) | |
| PVRL3 | POLIOVIRUS RECEPTOR-RELATED 3 | | 0.00054 (-1.6) | |
| PXN | PAXILLIN | | | 0.028 (-1.9) |
| QKI | QUAKING HOMOLOG, KH DOMAIN RNA BINDING (MOUSE) | | | 0.044 (-1.7) |
| R3HCC1 | R3H DOMAIN AND COILED-COIL CONTAINING 1 | 0.0091 (1.9) | | |
| RAB12 | RAB12, MEMBER RAS ONCOGENE FAMILY | | 0.0028 (-2.7) | |
| RABEPK | RAB9 EFFECTOR PROTEIN WITH KELCH MOTIFS | 0.013 (1.7) | | |
| RAD17 | RAD17 HOMOLOG (S. POMBE) | | 0.00033 (-2.2) | |
| RAD21 | RAD21 HOMOLOG (S. POMBE) | | 0.0044 (-1.7) | |
| RAG1AP1 | RECOMBINATION ACTIVATING GENE 1 ACTIVATING PROTEIN 1 | | 0.0000031 (-2.1) | |
| RANBP2 | RAN BINDING PROTEIN 2 | | | 0.021 (4.1) |
| RANBP3 | RAN BINDING PROTEIN 3 | | 0.0042 (-2.9) | |
| RASL11B | RAS-LIKE, FAMILY 11, MEMBER B | 0.0036 (1.7) | 0.0012 (-1.9) | |
| RBBP4 | N/A | 0.011 (1.7) | | |
| RBPJ | RECOMBINING BINDING PROTEIN SUPPRESSOR OF HAIRLESS (DROSOPHILA) | 0.0081 (1.7) | | |
| RDBP | RD RNA BINDING PROTEIN | | 0.0023 (-1.5) | |
| RECQL | RECQ PROTEIN-LIKE (DNA HELICASE Q1-LIKE) | 0.0092 (1.4) | | |
| RECQL | RECQ PROTEIN-LIKE (DNA HELICASE Q1-LIKE) | 0.0035 (2) | | |
| REEP3 | RECEPTOR ACCESSORY PROTEIN 3 | | 0.0015 | |

| | | | | |
|--------|---|-----------------|--------------------|-----------------|
| | | | (-1.7) | |
| REXO4 | REX4, RNA EXONUCLEASE 4 HOMOLOG (S. CEREVISIAE) | 0.0099 (2.3) | | |
| RFESD | LOC317671 | | 0.0043 (-3.1) | |
| RGS20 | REGULATOR OF G-PROTEIN SIGNALLING 20 | | 0.0031 (-3.3) | |
| RHOQ | RAS HOMOLOG GENE FAMILY, MEMBER Q | | 0.0046 (-1.6) | |
| RN7SK | RNA, 7SK, NUCLEAR | | 0.001 (2.4) | |
| RNF13 | RING FINGER PROTEIN 13 | | 0.003 (-6) | |
| RNF141 | RING FINGER PROTEIN 141 | | | 0.016 (-1.4) |
| RNF5 | RING FINGER PROTEIN 5 | | | 0.035 (1.5) |
| RNF7 | RING FINGER PROTEIN 7 | | 0.000064 (-1.6) | 0.035 (-1.3) |
| RPL14 | RIBOSOMAL PROTEIN L14 | | 0.0019 (1.7) | |
| RPL39L | RIBOSOMAL PROTEIN L39-LIKE | 0.011 (2.4) | | |
| RPN1 | RIBOPHORIN I | | 0.0037 (-1.5) | |
| RPS27 | RIBOSOMAL PROTEIN S27 (METALLOPANSTIMULIN 1) | | | 0.045 (-1.3) |
| RPS27A | RIBOSOMAL PROTEIN S27A | | | 0.043 (-1.2) |
| RRAD | RAS-RELATED ASSOCIATED WITH DIABETES | | | 0.0071 (-3) |
| RRS1 | RRS1 RIBOSOME BIOGENESIS REGULATOR HOMOLOG (S. CEREVISIAE) | | 0.00082 (-2) | |
| S100P | S100 CALCIUM BINDING PROTEIN P | | | 0.033 (-1.3) |
| SAMM50 | SORTING AND ASSEMBLY MACHINERY COMPONENT 50 HOMOLOG (S. CEREVISIAE) | 0.014 (1.8) | | |
| SCAMP2 | SECRETORY CARRIER MEMBRANE PROTEIN 2 | | 0.0017 (-1.6) | |
| SCO2 | SCO CYTOCHROME OXIDASE DEFICIENT HOMOLOG 2 (YEAST) | | 0.0015 (-1.7) | |
| SCP2 | STEROL CARRIER PROTEIN 2 | | 0.0032 (-5) | |
| SEC11A | SEC11-LIKE 1 (S. CEREVISIAE) | 0.012 (1.5) | | |
| SELS | SELENOPROTEIN S | | 0.0011 (-1.6) | |
| SELT | SELENOPROTEIN T | | 0.00052 (-1.7) | |

| | | | | |
|----------|--|-----------------|--------------------|-----------------|
| SEPSECS | SOLUBLE LIVER ANTIGEN/LIVER PANCREAS ANTIGEN | | | 0.044 (1.3) |
| SERF1B | SMALL EDRK-RICH FACTOR 1A (TELOMERIC) | | 0.0025 (-2) | 0.034 (-4.5) |
| SETBP1 | SET BINDING PROTEIN 1 | | 0.002 (1.9) | |
| SETD1A | SET DOMAIN CONTAINING 1A | | | 0.038 (1.5) |
| SETD3 | SET DOMAIN CONTAINING 3 | | 0.00023 (-2.2) | |
| SETP7 | SEPTIN 7 | | 0.003 (1.7) | |
| SH2D5 | SH2 DOMAIN CONTAINING 5 | | | 0.046 (-1.6) |
| SHMT2 | SERINE HYDROXYMETHYLTRANSFERASE 2 (MITOCHONDRIAL) | 0.014 (1.4) | | |
| SLC25A17 | "SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER; PEROXISOMAL MEMBRANE PROTEIN, 34KDA), MEMBER 17" | | 0.0032 (-1.6) | |
| SLC2A11 | SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 11 | | | 0.045 (-3.3) |
| SLC31A2 | SOLUTE CARRIER FAMILY 31 (COPPER TRANSPORTERS), MEMBER 2 | | 0.0012 (-1.6) | |
| SLC46A2 | THYMIC STROMAL CO-TRANSPORTER | | | 0.049 (1.3) |
| SLC5A3 | SOLUTE CARRIER FAMILY 5 (INOSITOL TRANSPORTERS), MEMBER 3 | | 0.0016 (-8.6) | |
| SLMAP | SARCOLEMMMA ASSOCIATED PROTEIN | 0.010 (1.5) | | |
| SLTM | HYPOTHETICAL PROTEIN FLJ10005 | | 0.0026 (-2.3) | |
| SNORD68 | HBII-202 SMALL NUCLEOLAR RNA | 0.011 (1.6) | | |
| SP100 | SP100 NUCLEAR ANTIGEN | | 0.00028 (-24.7) | |
| SP100 | SP100 NUCLEAR ANTIGEN | 0.0014 (1.9) | | |
| SPA17 | SPERM AUTOANTIGENIC PROTEIN 17 | | 0.0022 (-2.5) | |
| SPAG1 | SPERM ASSOCIATED ANTIGEN 1 | | | 0.020 (-4.6) |
| SPCS2 | SIGNAL PEPTIDASE COMPLEX SUBUNIT 2 HOMOLOG (S. CEREVISIAE) | | 0.000054 (-1.7) | |
| SPIN1 | SPINDLIN | | 0.0029 (-1.7) | |
| SRGAP2 | SLIT-ROBO RHO GTPASE ACTIVATING PROTEIN 2 | | | 0.044 (1.4) |
| SRP14P1 | SIMILAR TO SIGNAL RECOGNITION | 0.0076 | | |

| | | | | |
|---------|---|--------------|-----------------|--------------|
| | PARTICLE 14KDA (HOMOLOGOUS ALU RNA BINDING PROTEIN) | (1.4) | | |
| STAM2 | SIGNAL TRANSDUCING ADAPTOR MOLECULE (SH3 DOMAIN AND ITAM MOTIF) 2 | | | 0.033 (-2) |
| STC1 | STANNIOCALCIN 1 | 0.014 (2.9) | | |
| STEAP3 | STEAP FAMILY MEMBER 3 | | 0.00096 (1.9) | 0.036 (2.1) |
| STRA13 | N/A | 0.0033 (1.8) | | |
| STT3B | STT3, SUBUNIT OF THE OLIGOSACCHARYLTRANSFERASE COMPLEX, HOMOLOG B (S. CEREVISIAE) | | | 0.047 (-1.2) |
| SUGT1 | SGT1, SUPPRESSOR OF G2 ALLELE OF SKP1 (S. CEREVISIAE) | 0.0088 (1.6) | | |
| SULT1A3 | SULFOTRANSFERASE FAMILY, CYTOSOLIC, 1A, PHENOL-PREFERRING, MEMBER 3 | | 0.00086 (-1.7) | |
| SUPT6H | SUPPRESSOR OF TY 6 HOMOLOG (S. CEREVISIAE) | | 0.0000017 (1.8) | 0.020 (1.9) |
| SYTL2 | SYNAPTOTAGMIN-LIKE 2 | 0.014 (1.9) | 0.000046 (1.6) | |
| SYTL2 | SYNAPTOTAGMIN-LIKE 2 | 0.0078 (1.9) | | |
| TAF13 | TAF13 RNA POLYMERASE II, TATA BOX BINDING PROTEIN (TBP)-ASSOCIATED FACTOR, 18KDA | | 0.00023 (-3.5) | |
| TAPBPL | TAP BINDING PROTEIN-LIKE | | 0.0039 (-1.8) | |
| TBCC | TUBULIN-SPECIFIC CHAPERONE C | | 0.00058 (-4.1) | |
| TCEA3 | TRANSCRIPTION ELONGATION FACTOR A (SII), 3 | | | 0.0097 (2.3) |
| TCEAL3 | TRANSCRIPTION ELONGATION FACTOR A (SII)-LIKE 3 | | | 0.040 (1.9) |
| TCEAL8 | TRANSCRIPTION ELONGATION FACTOR A (SII)-LIKE 8 | 0.0085 (1.6) | | |
| TCTA | T-CELL LEUKEMIA TRANSLOCATION ALTERED GENE | | | 0.039 (-1.3) |
| TES | TESTIS DERIVED TRANSCRIPT (3 LIM DOMAINS) | | 0.0015 (-3.6) | |
| TFAP2A | TRANSCRIPTION FACTOR AP-2 ALPHA (ACTIVATING ENHANCER BINDING PROTEIN 2 ALPHA) | | 0.0003 (-2.4) | |
| TGIF1 | TGFB-INDUCED FACTOR (TALE FAMILY HOMEOBOX) | | | 0.040 (-1.6) |
| TIMM22 | TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 22 HOMOLOG (YEAST) | 0.0037 (1.6) | | |

| | | | | |
|-----------|--|-----------------|------------------|------------------|
| TIMM23 | TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 23 HOMOLOG (YEAST) | 0.013 (1.4) | | |
| TLR7 | TOLL-LIKE RECEPTOR 7 | | | 0.028 (2) |
| TM4SF18 | TRANSMEMBRANE 4 L SIX FAMILY MEMBER 18 | | 0.0044 (-1.7) | |
| TMBIM4 | TRANSMEMBRANE BAX INHIBITOR MOTIF CONTAINING 4 | | | 0.030 (-1.2) |
| TMEM185A | FAMILY WITH SEQUENCE SIMILARITY 11, MEMBER A | | 0.0033 (-1.5) | |
| TMEM41A | TRANSMEMBRANE PROTEIN 41A | 0.0086 (1.9) | | |
| TMEM5 | TRANSMEMBRANE PROTEIN 5 | 0.0029 (1.7) | 0.0031 (-1.6) | |
| TMEM54 | TRANSMEMBRANE PROTEIN 54 | | | 0.0094 (1.7) |
| TMUB2 | HYPOTHETICAL PROTEIN MGC3123 | | 0.0023 (-1.6) | |
| TNNT3 | TROPONIN T TYPE 3 (SKELETAL, FAST) | | | 0.040 (2) |
| TPMT | THIOPURINE S-METHYLTRANSFERASE | | | 0.011 (-1.7) |
| TPRKB | TP53RK BINDING PROTEIN | 0.0064 (1.5) | | |
| TPT1 | TUMOR PROTEIN, TRANSLATIONALLY-CONTROLLED 1 | | | 0.046 (-1.2) |
| TRIM32 | TRIPARTITE MOTIF-CONTAINING 32 | 0.002 (1.8) | | |
| TRIM5 | TRIPARTITE MOTIF-CONTAINING 5 | | 0.0011 (-3.1) | |
| TRIM5 | TRIPARTITE MOTIF-CONTAINING 5 | | 0.001 (-2.9) | |
| TRIM69 | RING FINGER PROTEIN 36 | 0.0089 (2.3) | 0.006 (-3.5) | |
| TTC25 | TETRATRICOPEPTIDE REPEAT DOMAIN 25 | | | 0.031 (2.1) |
| TTC32 | SIMILAR TO CG14894-PA | | 0.0031 (-1.9) | |
| TUBB2B | TUBULIN, BETA 2B | 0.0071 (1.8) | | |
| TUSC1 | TUMOR SUPPRESSOR CANDIDATE 1 | | 0.0021 (-1.7) | 0.038 (-1.6) |
| TWF1 | PTK9 PROTEIN TYROSINE KINASE 9 | | 0.0019 (-1.6) | |
| TXN | THIOREDOXIN | | 0.0036 (-2) | |
| U1SNRNPBP | U11/U12 SNRNP 35K | | 0.00064 (-4) | 0.046 (-2.2) |
| U1SNRNPBP | U11/U12 SNRNP 35K | | | 0.0086 (-1.5) |

| | | | | |
|---------|---|-----------------|---------------------|------------------|
| U2AF1 | U2(RNU2) SMALL NUCLEAR RNA AUXILIARY FACTOR 1 | 0.011 (1.6) | | |
| U2AF1L3 | U2(RNU2) SMALL NUCLEAR RNA AUXILIARY FACTOR 1-LIKE 3 | | 0.00002 (-4.6) | |
| U2AF1L4 | U2(RNU2) SMALL NUCLEAR RNA AUXILIARY FACTOR 1-LIKE 3 | | 0.00027 (-1.8) | |
| UBC | UBIQUITIN C | | 0.0000069 (-1.6) | 0.031 (-1.2) |
| UBC | UBIQUITIN C | | 0.0033 (-1.5) | |
| UBE2D3 | UBIQUITIN-CONJUGATING ENZYME E2D 3 (UBC4/5 HOMOLOG, YEAST) | | 0.0041 (-1.6) | |
| UBE2E3 | UBIQUITIN-CONJUGATING ENZYME E2E 3 (UBC4/5 HOMOLOG, YEAST) | | 0.00067 (-6.3) | |
| UBTD2 | DENDRITIC CELL-DERIVED UBIQUITIN-LIKE PROTEIN | | 0.004 (-3.8) | |
| UCHL3 | UBIQUITIN CARBOXYL-TERMINAL ESTERASE L3 (UBIQUITIN THIOLESTERASE) | | | 0.041 (-1.2) |
| UCK2 | URIDINE-CYTIDINE KINASE 2 | | 0.00024 (-1.7) | |
| UROS | N/A | 0.009 (2.2) | | |
| USF2 | UPSTREAM TRANSCRIPTION FACTOR 2, C-FOS INTERACTING | | | 0.049 (1.5) |
| USP10 | UBIQUITIN SPECIFIC PEPTIDASE 10 | 0.0072 (1.5) | | |
| USP26 | UBIQUITIN SPECIFIC PEPTIDASE 26 | | | 0.044 (1.8) |
| USP30 | UBIQUITIN SPECIFIC PEPTIDASE 30 | | 0.00036 (-2.2) | |
| USP33 | UBIQUITIN SPECIFIC PEPTIDASE 33 | | 0.00014 (-1.6) | |
| UTP11L | UTP11-LIKE, U3 SMALL NUCLEOLAR RIBONUCLEOPROTEIN, (YEAST) | | 0.0001 (-1.7) | |
| VAMP4 | VESICLE-ASSOCIATED MEMBRANE PROTEIN 4 | | | 0.014 (-2.6) |
| VAV3 | VAV 3 ONCOGENE | | 0.010 (-16.7) | 0.033 (-32.6) |
| WDR45 | WD REPEAT DOMAIN 45 | | 0.0024 (-4.1) | |
| WDR47 | WD REPEAT DOMAIN 47 | | 0.0015 (-2.3) | |
| WDSUB1 | WD REPEAT, STERILE ALPHA MOTIF AND U-BOX DOMAIN CONTAINING 1 | | | 0.048 (-1.2) |
| VEZT | VEZATIN, ADHERENS JUNCTIONS TRANSMEMBRANE PROTEIN | | 0.0007 (-1.8) | |
| WNT7A | WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 7A | 0.0029 (1.7) | | |
| VPS33A | VACUOLAR PROTEIN SORTING 33A (YEAST) | | 0.001 (-1.6) | |

| | | | | |
|---------|---|-----------------|--------------------|-----------------|
| VRK3 | VACCINIA RELATED KINASE 3 | 0.014 (1.7) | | |
| VSIG4 | V-SET AND IMMUNOGLOBULIN DOMAIN CONTAINING 4 | | | 0.0052 (1.7) |
| WTIP | WILMS TUMOR 1 INTERACTING PROTEIN | 0.012 (1.7) | | |
| XBP1 | X-BOX BINDING PROTEIN 1 | | 0.0023 (-1.7) | |
| YWHAE | TYROSINE 3- MONOOXYGENASE/TRYPHTOPHAN 5- MONOOXYGENASE ACTIVATION PROTEIN, EPSILON POLYPEPTIDE | | | 0.038 (1.3) |
| ZADH2 | HYPOTHETICAL PROTEIN BC010734 | | 0.0011 (-1.8) | |
| ZC3H14 | NUCLEAR PROTEIN UKP68 | | 0.0012 (-1.5) | |
| ZCD1 | CHROMOSOME 10 OPEN READING FRAME 70 | 0.014 (1.6) | | |
| ZDHC6 | ZINC FINGER, DHHC-TYPE CONTAINING 6 | | 0.00087 (-1.6) | 0.042 (-1.3) |
| ZFAND2A | ZINC FINGER, AN1-TYPE DOMAIN 2A | 0.0063 (2.2) | | |
| ZFAT1 | ZINC FINGER PROTEIN 406 | | | 0.037 (-3.1) |
| ZNF154 | ZINC FINGER PROTEIN 154 (PHZ-92) | 0.012 (-1.8) | | |
| ZNF160 | ZINC FINGER PROTEIN 160 | | 0.0038 (-1.7) | |
| ZNF195 | ZINC FINGER PROTEIN 195 | | 0.0025 (-5) | |
| ZNF200 | ZINC FINGER PROTEIN 200 | | 0.000063 (-2.3) | |
| ZNF200 | ZINC FINGER PROTEIN 200 | | 0.0021 (-1.7) | |
| ZNF277P | ZINC FINGER PROTEIN 277 | | 0.000047 (-3) | 0.029 (-2.5) |
| ZNF292 | ZINC FINGER PROTEIN 292 | | 0.00013 (-22.3) | |
| ZNF444 | ZINC FINGER PROTEIN 444 | | 0.00058 (-2) | |
| ZNF511 | ZINC FINGER PROTEIN 511 | 0.011 (1.8) | | |
| ZNF526 | ZINC FINGER PROTEIN 526 | | | 0.048 (-1.6) |
| ZNF557 | ZINC FINGER PROTEIN 557 | | 0.000042 (1.9) | |
| ZNF644 | HYPOTHETICAL PROTEIN BM-005 | | 0.0013 (-1.8) | |
| ZNF649 | ZINC FINGER PROTEIN 649 | 0.014 (1.4) | | |
| ZNF654 | ZINC FINGER PROTEIN 654 | | 0.0027 | |

| | | | | |
|--------|--------------------------------|--|-------------------|-----------------|
| | | | (-2.4) | |
| ZNF682 | ZINC FINGER PROTEIN 682 | | 0.00066 (-2.4) | |
| ZNF776 | HYPOTHETICAL PROTEIN FLJ38288 | | 0.0046 (-3) | |
| ZNF784 | SIMILAR TO ZINC FINGER PROTEIN | | | 0.042 (-1.9) |
| ZNHIT4 | ZINC FINGER, HIT TYPE 4 | | 0.00089 (-2.1) | |
| ZRANB2 | ZINC FINGER PROTEIN 265 | | 0.0014 (-1.6) | |